Diabetes Mellitus, Type 2 Clinical Research Trials

Huntsville : Medical Affiliated Research Center, Inc.

Do you struggle to manage your Type 2 Diabetes?

Huntsville : Medical Affiliated Research Center, Inc.

The MISSION Study - Are you interested in a clinical study for your diabetes?

Study to Evaluate the Pharmacodynamic and Pharmacokinetic Effects of LX4211 in Subjects With Type 2 Diabetes and Renal Impairment

Birmingham : Novo Nordisk Clinical Trial Call Center Updated

A Long-term, Randomised, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

Birmingham : Research Site

AMG 151 Amgen Protocol Number 20100761

Birmingham : 1245.25.10043 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Birmingham : 1245.25.10121 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Birmingham : University of Alabama at Birmingham

Changes in Bone Turnover With Exposure to a GLP-1 Receptor Agonist

Birmingham : Novo Nordisk Clinical Trial Call Center

Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes

Birmingham : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Birmingham : Research Site

Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes

Birmingham : 1276.1.10019 Boehringer Ingelheim Investigational Site

Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes

Birmingham : 1276.1.10014 Boehringer Ingelheim Investigational Site

Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes

Birmingham :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Birmingham : Univ Alabama At Birmingham

Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes

Birmingham : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin Therapy

Dothan :

Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes

Dothan :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Florence : 1276.10.11036 Boehringer Ingelheim Investigational Site

A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy

Huntsville : Pfizer Investigational Site

A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy

Huntsville : Medical Affiliated Research Center, Inc.

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Huntsville : 1245.25.10037 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Huntsville : GSK Investigational Site

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Engerix™-B in Adults With or Without Type 2 Diabetes Mellitus

Mobile : Wilmax Clinical Research, Inc.

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Mobile : 1245.25.10124 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Mobile :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Mobile : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

Montgomery : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)

Montgomery : Investigational Site Number 840324

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Muscle Shoals : Call for Information (Investigational Site 0066) Updated

A Study to Assess Cardiovascular Outcomes Following Treatment With MK-3102 in Participants With Type 2 Diabetes Mellitus (MK-3102-018 AM5)

Muscle Shoals :

Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes

Muscle Shoals : Terence T. Hart, Md

Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes

Muscle Shoals :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Ozark : Iicr, Inc. (International Institute Of Clinical Research)

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Pell City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

Little Rock : 1245.25.10015 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Chandler : Radiant Research - Phoenix

Diabetes (Type 2) Research Study

Phoenix : Southwest Center for HIV/AIDS

Are You Living with HIV and Have Type 2 Diabetes?

Phoenix : Arizona Research Center Updated

Diabetes Mellitus Type II

Phoenix : Premier Research Clinical Research Centers - Phoenix

Do you have trouble controlling your type 2 diabetes with diet and exercise and metformin? If so, this medical research study may be for you.

Tucson : Radiant Research - Tucson

Type 2 Diabetes Research Opportunity

550 East Orange Street : Clinical Research Unit

Effect of Pioglitazone on Mitochondrial Function in Muscle and Adipose Tissue in Humans

Chandler : Call for Information (Investigational Site 0013) Updated

A Study to Assess Cardiovascular Outcomes Following Treatment With MK-3102 in Participants With Type 2 Diabetes Mellitus (MK-3102-018 AM5)

Chandler : Investigational Site Number 840273

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Cottonwood :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Gilbert : Call for Information (Investigational Site 0001)

A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM1)

Gilbert : Call for Information (Investigational Site 0037) Updated

A Study to Assess Cardiovascular Outcomes Following Treatment With MK-3102 in Participants With Type 2 Diabetes Mellitus (MK-3102-018 AM5)

Gilbert : 1245.25.10056 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Glendale : Pfizer Investigational Site

A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy

Glendale : 1276.1.10010 Boehringer Ingelheim Investigational Site

Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes

Goodyear :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Goodyear : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin Therapy

Green Valley : Eclipse Clinical Research

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Green Valley : Eclipse Clinical Research

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Green Valley : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Hot Springs : 1218.56.01002 Boehringer Ingelheim Investigational Site

Finding a Safe and Effective Dose of Linagliptin in Pediatric Patients With Type 2 Diabetes

Mesa :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Mesa : Investigational Site Number 840217

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Mesa :

Comparison of TAK-875 to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes

Mesa : Clinical Research Advantage/Desert Clinical Research, LLC

Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus

Mesa : Desert Clinical Research

Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes

Peoria : 1245.25.10175 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Peoria : Investigational Site Number 840220

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Peoria :

Comparison of TAK-875 to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes

Phoenix : Central Phoenix Medical Clinic

A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone

Phoenix : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study Comparing the Effect of Dulaglutide With Liraglutide in Type 2 Diabetes

Phoenix : 43rd Medical Associates

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Phoenix : 43rd Medical Associates

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Phoenix : Hope Research Institute

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Phoenix : Call for Information (Investigational Site 0003)

A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM1)

Phoenix : Updated

A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities

Phoenix : Call for Information (Investigational Site 0076) Updated

A Study to Assess Cardiovascular Outcomes Following Treatment With MK-3102 in Participants With Type 2 Diabetes Mellitus (MK-3102-018 AM5)

Phoenix : 1245.25.10072 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Phoenix :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Phoenix : Investigational Site Number 840207

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Phoenix : Investigational Site Number 840211

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Phoenix :

Comparison of TAK-875 to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes

Phoenix :

Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes

Phoenix : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Phoenix : Central Phoenix Medical Clinic

Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus

Phoenix : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

Phoenix : Clinical Research Advantage, Inc

Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes

Phoenix : Stonecreek Medical Associates, Pc/Clinical Research Advantag

Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes

Phoenix : Clinical Research Advantage, Inc

Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes

Phoenix :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Phoenix : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin Therapy

Tempe : Central Phoenix Medical Center

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Tempe : Clinical Research Advantage/Desert Clinical Research

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Tempe : Clinical Research Advantage/Desert Clinical Research

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Tempe : Central Phoenix Medical Clinic, Llc

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Tempe : Investigational Site Number 840234

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Tempe : Investigational Site Number 840264

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Tempe :

Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes

Tempe : Cassidy Medical Group/Clinical Research Advantage

Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes

Tempe : Clinical Research Advantage, Inc.

Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes

Tempe : Clinical Research Advantage, Inc./ Stonecreek Medical Associates, Pc

Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes

Tempe :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Tucson : Visions Clinical Research - Tucson

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Tucson : Visions Clinical Research - Tucson

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Tucson : Call for Information (Investigational Site 0004) Updated

A Study to Assess Cardiovascular Outcomes Following Treatment With MK-3102 in Participants With Type 2 Diabetes Mellitus (MK-3102-018 AM5)

Tucson : Research Site

AMG 151 Amgen Protocol Number 20100761

Tucson :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Tucson :

Colesevelam Pediatric Type 2 Diabetes Mellitus Study

Tucson : Desert Sun Clinical Research, LLC

Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus

Tucson : Desert Sun Clinical Research, LLC

Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus

Tucson : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

Tucson : Research Site

Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes

Tucson :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Jonesboro : NEA Baptist Clinic - Clinical Research Center

Are you a diabetic with cardiovascular disease that has recently been hospitalized for a coronary event?

Jonesboro : NEA Baptist Clinic - Clinical Research Center

Do you have Type 2 Diabetes and high cardiovascular risk?

Little Rock : Lynn Institute of the Ozarks

Lynn Institute is currently conducting a clinical research study of an investigational medication for type 2 diabetes. For more information, please call the Lynn Institute at 501-975-2000.

Jonesboro : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Little Rock : Pfizer Investigational Site

A Phase 2 Multi-Center Study To Evaluate The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist In Adults With Type 2 Diabetes And Overt Nephropathy

Little Rock : Aureus Research, Inc.

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Little Rock : Aureus Research, Inc.

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Little Rock : Preferred Research Partners, Inc.

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Little Rock : Research Site

AMG 151 Amgen Protocol Number 20100761

Little Rock : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Observational Study to Understand Challenges Associated With Progression of Insulin Therapy in Type 2 Diabetes

Little Rock :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Little Rock :

Colesevelam Pediatric Type 2 Diabetes Mellitus Study

Little Rock : Investigational Site Number 840304

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Little Rock : Investigational Site Number 840003

Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients

Little Rock : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

Malvern :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Pine Bluff : Paul W. Davis, MD, Private Practice

Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus

Pine Bluff : Paul W. Davis, MD, PA

Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus

Searcy :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

White Hall :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Anaheim : Anaheim Clinical Trials (ACT)

High Blood Sugar Levels can affect Your Health.

Anaheim : Anaheim Clinical Trials (ACT)

Patients with type 2 diabetes needed for a clinical research trial.

Burbank : Providence Clinical Research

Is Diabetes a Part of Your Life?

Escondido : AMCR Institute, Inc. Updated

41- Week Study to Confirm the Efficacy of Insulin Degludec Compared to Placebo, Both in Combination With Liraglutide and Metformin in Controlling Glycaemia in Patients with Diabetes Mellitus Type 2

Escondido : AMCR Institute, Inc. Updated

A 26-week Study to Compare the Efficacy and Safety of Lixisenatide to Insulin Glutisine in Patients with Diabetes Mellitus Type 2

Escondido : AMCR Institute, Inc. Updated

A 52- Week Study to Compare the Glycemic Effects, Safety and Tolerability of Exenatide Once Weekly Compared to Exenatide Twice Daily in Patients with Diabetes Mellitus Type 2

Irvine : Irvine Center for Clinical Research

Could a potential new once-weekly type 2 diabetes medication help you find HARMONY?

Long Beach : Novo Research, Inc.

Type 2 Diabetes with inadequately controlled Hypertension

Paramount : Center for Clinical Trials, LLC

¿Es usted una persona con diabetes de tipo 2, de 30 a 70 años de edad, a la que se está tratando con metformina sola o con metformina en combinación con una sulfonilurea como gliburida (Diabeta), glipizida (Glucotrol), repaglinida (Prandin)?

Paramount : Center for Clinical Trials, LLC

¿Se le ha diagnosticado diabetes de tipo 2?

Paramount : Center for Clinical Trials, LLC

Are you a type 2 diabetic between 30 and 70 years of age and currently being treated with either Metformin alone or Metformin in combination with Sulfonylurea such as Glyburide (Diabeta), Glipizide (Glucotrol), Repaglinide (Prandin)?

Paramount : Center for Clinical Trials, LLC

Have you been diagnosed with Type 2 Diabetes?

Paramount : Center for Clinical Trials, LLC

Uncontrolled Blood Sugar? Take Control. Let us Help.

Sacramento : Sutter Institute for Medical Research (SIMR)

Diabetes Type 2

Sacramento : Sutter Institute for Medical Research (SIMR)

Diabetes Type 2

San Diego : Wetlin Research Associates, Inc.

Type 2 Diabetes Study

San Gabriel : California Center for Clinical Research

A study evaluating the cardiovascular outcomes in type 2 diabetic patients after a heart attack or unstable angina

Santa Ana : Research Across America

Diabetes

Santa Ana : Apex Research Institute

Diabetes Type 2 Study

Santa Ana : Coastal Multi-Specialty Research

TAKEDA EXAMINE trial patients for who have Type II diabetes & ACS coronary artery disease, post angiogram or heart attack. This is a phase 3b study. Currently open for enrollment.

Santa Ana : Coastal Multi-Specialty Research

TECOS -DM II . A randomized, placebo controlled clinical Trial to Evaluate Cardiovascular Outcomes after treatment with Sitagliptin in patients with diabetes with inadequate glycemic control.

Walnut Creek : Diablo Clinical Research

Can you tell me about the study drug?

Walnut Creek : Diablo Clinical Research

Diabetes Shouldn’t Define You

Walnut Creek : Diablo Clinical Research

Do you have type 2 diabetes?

Walnut Creek : Diablo Clinical Research

Do you have Type 2 Diabetes? Consider Volunteering?

Walnut Creek : Diablo Clinical Research

Do you have Type 2 Diabetes? We are enrolling adult volunteers now.

Walnut Creek : Diablo Clinical Research

Do you Have Type 2 Diabetes? We are enrolling adult volunteers now.

Walnut Creek : Diablo Clinical Research

From diagnosis to decision. If you have type 2 diabetes there are a few things you should know

Walnut Creek : Diablo Clinical Research

Have you been diagnosed with Type II Diabetes?

Walnut Creek : Diablo Clinical Research

Raise your hand if you have type 2 diabetes

Walnut Creek : Diablo Clinical Research

When your type 2 diabetes is out of control, finding harmony is essential

Walnut Creek : Diablo Clinical Research

You may be eligible to join the EMERGE STUDY if you

Anaheim : Novo Nordisk Clinical Trial Call Center Updated

A Long-term, Randomised, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

Anaheim : Orange County Research Institute

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Anaheim : Research Site

AMG 151 Amgen Protocol Number 20100761

Anaheim : Pfizer Investigational Site

Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus

Anaheim :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Anaheim : Call for Information (Investigational Site 0082)

Study to Assess Safety & Efficacy of Sitagliptin as Initial Monotherapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants (MK-0431-083 AM1)

Anaheim : Novo Nordisk Clinical Trial Call Center

The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes

Anaheim : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy

Bell Gardens : Investigational Site Number 840347

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Burlingame : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

Canoga Park : Call for Information (Investigational Site 0101)

A Study of the Safety and Efficacy of MK-0431A in Pediatric Participants With Type 2 Diabetes Mellitus (MK-0431A-170 AM1)

Canoga Park : Call for Information (Investigational Site 0012)

Study to Assess Safety & Efficacy of Sitagliptin as Initial Monotherapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants (MK-0431-083 AM1)

Carmichael : Med Center

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Chino : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study Comparing the Effect of Dulaglutide With Liraglutide in Type 2 Diabetes

Chino :

A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Sulfonylurea Alone or Sulfonylurea Plus Metformin Therapy

Chino :

A Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus Who Have Not Previously Received Anti-Hyperglycemic Therapy

Chino : Catalina Research Institute, Llc

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Chino : Catalina Research Institute, Llc

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Chula Vista : Pfizer Investigational Site

A 6-Week Study Of PF-05175157 In Type 2 Diabetes Mellitus

Chula Vista : Site 18

A Study to Evaluate Safety and Efficacy of TTP054 for 12 Weeks in Subjects With Type 2 Diabetes

Chula Vista : Research Site

AMG 151 Amgen Protocol Number 20100761

Chula Vista :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Chula Vista :

Comparison of TAK-875 to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes

Chula Vista : Investigational Site Number 840005

Evaluation of the Blood Levels of the Drug (Lixisenatide), the Plasma Glucose Levels and Safety in Paediatric and Adult Patients With Type 2 Diabetes

Chula Vista : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Chula Vista : Profil Institute for Clinical Research

Mechanistic Study of ISIS ISIS-APOCIIIRX in Type 2 Diabetes

Chula Vista : Pfizer Investigational Site

Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus

Chula Vista : Lexicon Investigational Site

Study to Evaluate the Pharmacodynamic and Pharmacokinetic Effects of LX4211 in Subjects With Type 2 Diabetes and Renal Impairment

Clovis : Call for Information (Investigational Site 0015)

A Study of the Safety and Efficacy of MK-0431A in Pediatric Participants With Type 2 Diabetes Mellitus (MK-0431A-170 AM1)

Clovis : Call for Information (Investigational Site 0013)

Study to Assess Safety & Efficacy of Sitagliptin as Initial Monotherapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants (MK-0431-083 AM1)

Concord : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Covina : Pfizer Investigational Site

A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy

Cudahy : Updated

A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities

Danville : Novo Nordisk Clinical Trial Call Center

The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes

Danville : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin Therapy

Downey :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Encinitas : Call for Information (Investigational Site 0053) Updated

A Study to Assess Cardiovascular Outcomes Following Treatment With MK-3102 in Participants With Type 2 Diabetes Mellitus (MK-3102-018 AM5)

Encino : Call for Information (Investigational Site 0008)

A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM1)

Encino : 1245.25.10103 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Escondido :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Escondido : Investigational Site Number 840244

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Fair Oaks : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin Therapy

Fountain Valley : Southland Clinical Research Center, Inc.

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Fountain Valley : Southland Clinical Research Center, Inc.

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Fountain Valley : Southland Clinical Research Center, Inc.

Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus

Fountain Valley : Southland Clinical Research Center, Inc.

Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus

Fresno : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study Comparing the Effect of Dulaglutide With Liraglutide in Type 2 Diabetes

Fresno : Research Site

AMG 151 Amgen Protocol Number 20100761

Fresno : 1245.25.10158 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Fresno : Investigational Site Number 840257

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Fresno : Research Center of Fresno

Evaluate Safety of Technosphere® Insulin Inhalation Powder (TI Inhalation Powder) on Diabetic Subjects With Mild Obstructive Pulmonary Disease

Fresno : Valley Research

Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus

Fresno :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Fresno : Novo Nordisk Clinical Trial Call Center

The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes

Fresno : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin Therapy

Glendale : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)

Greenbrae : Novo Nordisk Clinical Trial Call Center Updated

A 26-week Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart BID and Insulin Degludec OD Plus Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin in Need of Treatment Intensification With Mealtime Insulin

Greenbrae : Novo Nordisk Clinical Trial Call Center Updated

A Long-term, Randomised, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

Greenbrae : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)

Greenbrae : Marin Endocrine Care & Research, Inc.

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Greenbrae : Marin Endocrine Care & Research, Inc.

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Greenbrae : Call for Information (Investigational Site 0010)

A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM1)

Greenbrae : Research Site

AMG 151 Amgen Protocol Number 20100761

Greenbrae : Investigational Site Number 840213

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Greenbrae : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Greenbrae : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin Therapy

Harbor City : 1245.25.10126 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Hawaiian Gardens :

A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin Alone

Hillsborough : Call for Information (Investigational Site 0002) Updated

Addition of MK-3102 to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin (MK-3102-022 AM3)

Huntingdon Beach : Call for Information (Investigational Site 0001) Updated

Addition of MK-3102 to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin (MK-3102-022 AM3)

Huntington Beach :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Huntington Beach : Investigational Site Number 840267

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Huntington Beach : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Huntington Beach : 1276.1.10006 Boehringer Ingelheim Investigational Site

Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes

Huntington Beach : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin Therapy

Huntington Park : Del Rosario Medical Clinic, Inc.

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Huntington Park : Time Clinical Research Inc.

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Huntington Park : Time Clinical Research Inc.

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Huntington Park : Del Rosario Medical Clinic, Inc.

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Huntington Park : Call for Information (Investigational Site 0088) Updated

A Study to Assess Cardiovascular Outcomes Following Treatment With MK-3102 in Participants With Type 2 Diabetes Mellitus (MK-3102-018 AM5)

Huntington Park :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Huntington Park : Del Rosario Medical Clinic, Inc.

Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus

Inglewood : Research Site

AMG 151 Amgen Protocol Number 20100761

Inglewood :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

La Jolla : Investigational Site Number 840230

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

La Jolla : Investigational Site Number 840235

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

La Jolla : Scripps Whittier Diabetes Institute

Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus

La Jolla : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy

La Mesa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)

La Mesa : Investigational Site Number 840274

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

La Mesa :

Comparison of TAK-875 to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes

La Mesa :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Laguna Hills :

Comparison of TAK-875 to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes

Laguna Hills : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Laguna Hills :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Lakewood : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

Lancaster : 1245.25.10001 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Lancaster : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin Therapy

Lincoln : Updated

A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities

Lincoln : Call for Information (Investigational Site 0026) Updated

A Study to Assess Cardiovascular Outcomes Following Treatment With MK-3102 in Participants With Type 2 Diabetes Mellitus (MK-3102-018 AM5)

Lomita : 1276.10.11040 Boehringer Ingelheim Investigational Site

A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy

Lomita : Marina Raikhel, M.D., F.A.A.F.P

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Lomita : Research Site

AMG 151 Amgen Protocol Number 20100761

Lomita :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Lomita : Torrance Clinical Research

Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes

Lomita : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin Therapy

Long Beach :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Long Beach : Investigational Site Number 840222

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Long Beach : Novo Nordisk Clinical Trial Call Center

Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes

Long Beach :

Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes

Long Beach : Health Care Partners Medical Group

Evaluate Safety of Technosphere® Insulin Inhalation Powder (TI Inhalation Powder) on Diabetic Subjects With Mild Obstructive Pulmonary Disease

Long Beach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

Long Beach : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy

Long Beach : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin Therapy

Los Angeles : Novo Nordisk Clinical Trial Call Center Updated

A 26-week Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart BID and Insulin Degludec OD Plus Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin in Need of Treatment Intensification With Mealtime Insulin

Los Angeles : Novo Nordisk Clinical Trial Call Center Updated

A Long-term, Randomised, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

Los Angeles : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)

Los Angeles : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study Comparing the Effect of Dulaglutide With Liraglutide in Type 2 Diabetes

Los Angeles :

A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Sulfonylurea Alone or Sulfonylurea Plus Metformin Therapy

Los Angeles : American Institute Of Research

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Los Angeles : Randall G. Shue, D.O.

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Los Angeles : American Institute Of Research

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Los Angeles : Clinica Medica San Miguel

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Los Angeles : Randall G. Shue, D.O.

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Los Angeles : Call for Information (Investigational Site 0020)

A Study of the Safety and Efficacy of MK-0431A in Pediatric Participants With Type 2 Diabetes Mellitus (MK-0431A-170 AM1)

Los Angeles : Call for Information (Investigational Site 0049) Updated

A Study to Assess Cardiovascular Outcomes Following Treatment With MK-3102 in Participants With Type 2 Diabetes Mellitus (MK-3102-018 AM5)

Los Angeles : Call for Information (Investigational Site 0050) Updated

A Study to Assess Cardiovascular Outcomes Following Treatment With MK-3102 in Participants With Type 2 Diabetes Mellitus (MK-3102-018 AM5)

Los Angeles : Call for Information (Investigational Site 0002)

A Study to Assess the Pharmacokinetics and the Ability for Pediatric Participants With Type 2 Diabetes to Swallow MK-0431A XR Tablets (MK-0431A-296)

Los Angeles : Site 1

A Study to Evaluate Safety and Efficacy of TTP054 for 12 Weeks in Subjects With Type 2 Diabetes

Los Angeles : Research Site

AMG 151 Amgen Protocol Number 20100761

Los Angeles :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Los Angeles :

Colesevelam Pediatric Type 2 Diabetes Mellitus Study

Los Angeles : Novo Nordisk Clinical Trial Call Center

Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes

Los Angeles : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Los Angeles : National Research Institute

Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus

Los Angeles : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

Los Angeles : Andrew J. Lewin Medical Corporation DBA National Research Institute

Safety and Efficacy of BGP-15 in Patients With Type 2 Diabetes Mellitus

Los Angeles : 1276.1.10009 Boehringer Ingelheim Investigational Site

Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes

Los Angeles : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Study of How Dulaglutide Compares to Placebo in Participants With Type 2 Diabetes Who Are Also on Sulfonylurea Therapy (AWARD-8)

Los Angeles : Call for Information (Investigational Site 0018)

Study to Assess Safety & Efficacy of Sitagliptin as Initial Monotherapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants (MK-0431-083 AM1)

Los Angeles : Neufeld Medical Group

Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes

Los Angeles : Novo Nordisk Clinical Trial Call Center

The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes

Los Angeles : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy

Los Gatos : Office Of Richard S. Cherlin, Md

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Los Gatos : 1245.25.10047 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Los Gatos :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Merced :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Mission Hills : Novo Nordisk Clinical Trial Call Center Updated

A 26-week Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart BID and Insulin Degludec OD Plus Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin in Need of Treatment Intensification With Mealtime Insulin

Mission Hills :

Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes

Mission Hills :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Modesto : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)

Moreno Valley : Spectrum Clinical Research Institute, Inc

Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus

Moreno Valley : Spectrum Clinical Research Institute, Inc

Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus

National City : 1245.25.10084 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Newport Beach :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

North Hollywood :

Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes

Northridge : Novo Nordisk Clinical Trial Call Center Updated

A Long-term, Randomised, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

Northridge : Diabetes Medical Center Of California

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Northridge : Diabetes Medical Center Of California

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Northridge :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Northridge : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Northridge : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

Northridge : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin Therapy

Norwalk : Lucita M. Cruz,Md.,Inc.

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Norwalk : Lucita M. Cruz,Md.,Inc.

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Oceanside : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Orange : Sds Clinical Trials

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Orange : Sds Clinical Trials

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Palm Desert : Research Site

AMG 151 Amgen Protocol Number 20100761

Palm Springs : Call for Information (Investigational Site 0065) Updated

A Study to Assess Cardiovascular Outcomes Following Treatment With MK-3102 in Participants With Type 2 Diabetes Mellitus (MK-3102-018 AM5)

Palm Springs : 1245.25.10118 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Palm Springs : Investigational Site Number 840243

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Palo Alto : Novo Nordisk Clinical Trial Call Center

Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes

Paramount : Bayview Research Group, Llc

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Paramount :

Comparison of TAK-875 to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes

Paramount : Center for Clinical Trials, LLC.

Safety and Efficacy of BGP-15 in Patients With Type 2 Diabetes Mellitus

Paramount :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Pismo Beach :

Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes

Pismo Beach :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Pomona :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Poway : San Diego Managed Care Group

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Poway : Call for Information (Investigational Site 0009)

A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM1)

Riverside :

A Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus Who Have Not Previously Received Anti-Hyperglycemic Therapy

Riverside : Integrated Research Group, Inc.

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Riverside : 1245.25.10061 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Roseville : Updated

A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities

Roseville : Research Site

AMG 151 Amgen Protocol Number 20100761

Sacramento : Quality Control Research, Inc

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Sacramento : Quality Control Research, Inc

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Sacramento : Call for Information (Investigational Site 0022)

A Study of the Safety and Efficacy of MK-0431A in Pediatric Participants With Type 2 Diabetes Mellitus (MK-0431A-170 AM1)

Sacramento : Updated

A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities

Sacramento : Sacramento Heart and Vascular Medical Associates

Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus

Sacramento : Sacramento Heart and Vascular Medical Associates

Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus

Sacramento : Call for Information (Investigational Site 0020)

Study to Assess Safety & Efficacy of Sitagliptin as Initial Monotherapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants (MK-0431-083 AM1)

Sacramento : Perinatal And Pediatric Endocrinology

Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes

Salinas : Diabetes Care Center

CGM Evaluation of Glucose Excursions in Basal Insulin Treated T2DM at Fasting Glucose Target

San Diego : Wetlin Research Associates, Inc.

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

San Diego : Call for Information (Investigational Site 0021)

A Study of the Safety and Efficacy of MK-0431A in Pediatric Participants With Type 2 Diabetes Mellitus (MK-0431A-170 AM1)

San Diego : Call for Information (Investigational Site 0015)

A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM1)

San Diego : Research Site

AMG 151 Amgen Protocol Number 20100761

San Diego : 1245.25.10040 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

San Diego : 1245.25.10055 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

San Diego : 1245.25.10193 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

San Diego :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

San Diego :

Colesevelam Pediatric Type 2 Diabetes Mellitus Study

San Diego :

Comparison of TAK-875 to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes

San Diego : Accelovance Inc.

Evaluation and Comparison of Noninvasive Blood Glucose Concentrations

San Diego : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

San Diego : Research Site

Investigate Effect of AMG 151 on 24-hour Ambulatory Blood Pressure & Glucose Levels in Type 2 Diabetes Mellitus Subjects

San Diego : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

San Diego : Research Site

Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes

San Diego :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

San Diego : Call for Information (Investigational Site 0019)

Study to Assess Safety & Efficacy of Sitagliptin as Initial Monotherapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants (MK-0431-083 AM1)

San Diego : Rady Children'S Hospital - San Diego

Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes

San Dimas : Pfizer Investigational Site

A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy

San Dimas :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

San Francisco : Center For Clinical Research Inc.

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

San Francisco : Center For Clinical Research Inc.

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

San Jose : Research Site

AMG 151 Amgen Protocol Number 20100761

San Mateo : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

San Mateo : Novo Nordisk Clinical Trial Call Center

The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes

San Mateo : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy

San Mateo : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin Therapy

Santa Ana :

A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin Alone

Santa Ana :

A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Sulfonylurea Alone or Sulfonylurea Plus Metformin Therapy

Santa Ana :

A Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus Who Have Not Previously Received Anti-Hyperglycemic Therapy

Santa Ana : Crest Clinical Trials, Inc.

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Santa Ana : Crest Clinical Trials, Inc.

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Santa Ana : Call for Information (Investigational Site 0129)

A Study of the Efficacy and Safety of MK-0431D (a Fixed-dose Combination of Sitagliptin and Simvastatin) for the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-266 AM1)

Santa Ana :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Santa Clarita : Clearview Medical Research, LLC

A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone

Santa Clarita : Clearview Medical Research LLC

Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus

Santa Monica : Novo Nordisk Clinical Trial Call Center Updated

A Long-term, Randomised, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

Santa Monica : Orrin M. Troum, Md And Medical Associates

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Santa Monica : Orrin M. Troum, Md And Medical Associates

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Santa Rosa : 1245.25.10027 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Spring Valley : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study Comparing the Effect of Dulaglutide With Liraglutide in Type 2 Diabetes

Spring Valley : Call for Information (Investigational Site 0006)

A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM1)

Spring Valley : Investigational Site Number 840250

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Stanford : Stanford University School of Medicine

Rosiglitazone-Induced Weight Gain

Stockton : 1245.25.10074 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Stockton :

Comparison of TAK-875 to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes

Stockton :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Suwanee :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Tarzana : Call for Information (Investigational Site 0011)

A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM1)

Tarzana : Call for Information (Investigational Site 0024) Updated

A Study to Assess Cardiovascular Outcomes Following Treatment With MK-3102 in Participants With Type 2 Diabetes Mellitus (MK-3102-018 AM5)

Tarzana : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin Therapy

Temecula : Investigational Site Number 840209

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Temecula : Investigational Site Number 840002

Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients

Thousand Oaks :

A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin Alone

Thousand Oaks :

A Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus Who Have Not Previously Received Anti-Hyperglycemic Therapy

Torrance : Torrance Clinical Research

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Torrance : Updated

A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities

Torrance : Investigational Site Number 840297

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Torrance : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Torrence :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Tustin : University Clinical Investigators, Inc.

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Tustin : Orange County Research Center

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Tustin : Orange County Research Center

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Tustin : University Clinical Investigators, Inc.

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Tustin : Updated

A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities

Tustin : Call for Information (Investigational Site 0086) Updated

A Study to Assess Cardiovascular Outcomes Following Treatment With MK-3102 in Participants With Type 2 Diabetes Mellitus (MK-3102-018 AM5)

Tustin : Call for Information (Investigational Site 0015)

A Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of MK-3102 to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy (MK-3102-024 AM3)

Tustin : Investigational Site Number 840272

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Tustin : Orange County Research Center

Safety and Efficacy of BGP-15 in Patients With Type 2 Diabetes Mellitus

Tustin : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Study of How Dulaglutide Compares to Placebo in Participants With Type 2 Diabetes Who Are Also on Sulfonylurea Therapy (AWARD-8)

Tustin : Novo Nordisk Clinical Trial Call Center

The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes

Valencia : 1245.25.10083 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Ventura : Novo Nordisk Clinical Trial Call Center Updated

A Long-term, Randomised, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

Ventura : Call for Information (Investigational Site 0457) Updated

A Study of the Safety and Efficacy of MK-0431A XR in Pediatric Participants With Type 2 Diabetes Mellitus (MK-0431A-289 AM2)

Ventura :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Ventura : Ronald Chochinov Md Inc

Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes

Ventura : Novo Nordisk Clinical Trial Call Center

The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes

Victorville : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Vista : Cassidy Medical Group/Clinical Research Advantage

Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes

Walnut Creek : Research Site

AMG 151 Amgen Protocol Number 20100761

Walnut Creek : Investigational Site Number 840223

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Walnut Creek : Pfizer Investigational Site

Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus

Walnut Creek : Novo Nordisk Clinical Trial Call Center

The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes

Walnut Creek : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy

Watsonville : Research Site

AMG 151 Amgen Protocol Number 20100761

West Hills : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)

West Hills : Infosphere Clinical Research

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

West Hills :

Comparison of TAK-875 to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes

West Hills : Infosphere Clinical Research

Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus

West Hills : Infosphere Clinical Research

Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus

West Hills : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin Therapy

Westlake Village :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Whittier : Pfizer Investigational Site

A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy

Yuba City : Pfizer Investigational Site

A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy

Denver : Radiant Research - Denver

Diabetes (Type 2) Research Study

Denver : Horizons Clinical Research Center, LLC

Horizons Clinical Research Center, LLC is now enrolling volunteers to participate in a clinical research study for the treatment of type 2 diabetes.

Denver : Radiant Research - Denver

Type 2 Diabetes Research Opportunity

Longmont : Longmont Medical Research Network

Research Study for Type 2 Diabetes

Longmont : Longmont Medical Research Network

Research Study for Type 2 Diabetes

Aurora : Novo Nordisk Clinical Trial Call Center Updated

A Long-term, Randomised, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

Aurora : Call for Information (Investigational Site 0024)

A Study of the Safety and Efficacy of MK-0431A in Pediatric Participants With Type 2 Diabetes Mellitus (MK-0431A-170 AM1)

Aurora :

Colesevelam Pediatric Type 2 Diabetes Mellitus Study

Aurora : University of Colorado Anschutz Medical Campus

Evaluating the Effects of a Study Medication on Exercise Function in Type 2 Diabetes

Aurora : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Aurora : University of Colorado Anschutz Medical Campus

Impact of Exenatide on Cardiovascular Exercise Performance in Type 2 Diabetes

Aurora : Research Site

Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes

Aurora : Call for Information (Investigational Site 0023)

Study to Assess Safety & Efficacy of Sitagliptin as Initial Monotherapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants (MK-0431-083 AM1)

Aurora : Children'S Hospital Colorado

Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes

Colorado Springs : Cra/Cshp

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Colorado Springs : Cra/Cshp

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Colorado Springs : 1245.25.10144 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Colorado Springs :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Colorado Springs : Investigational Site Number 840249

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Colorado Springs : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin Therapy

Denver : Novo Nordisk Clinical Trial Call Center Updated

A Long-term, Randomised, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

Denver : Denver Internal Medicine Group

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Denver : Site 13

A Study to Evaluate Safety and Efficacy of TTP054 for 12 Weeks in Subjects With Type 2 Diabetes

Denver : 1245.25.10085 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Denver : 1245.25.10153 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Denver : Investigational Site Number 840331

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Denver : Investigational Site Number 840041

Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients

Denver : University of Colorado

FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)

Denver : Creekside Endocrine Associates PC

Safety and Efficacy of BGP-15 in Patients With Type 2 Diabetes Mellitus

Denver : 1276.1.10001 Boehringer Ingelheim Investigational Site

Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes

Golden : New West Physicians, Pc

Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes

Lakewood :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Littleton : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Northglenn : 1276.1.10003 Boehringer Ingelheim Investigational Site

Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes

New London : Coastal Connecticut Research, LLC

Do you have Diabetes?

Waterbury : Chase Medical Research, LLC

A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, Multicenter Study, to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sulphonylurea Therapy.

Waterbury : Chase Medical Research, LLC

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Subjects with Type 2 Diabetes with Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB).

Waterbury : Chase Medical Research, LLC

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Subjects with Type 2 Diabetes with Inadequately Controlled Hypertension treated with an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) and an Additional Antihypertensive Medication.

Waterbury : Chase Medical Research, LLC

A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Co-Administration of Sitagliptin and Atorvastatin in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin Monotherapy.

Waterbury : Chase Medical Research, LLC

A Phase III, multicentre, international, randomised, parallel group, double blind cardiovascular safety study of BI 10773 (10 mg and 25 mg administered orally once daily) compared to usual care in type 2 diabetes mellitus patients with increased cardiovascular risk.

Waterbury : Chase Medical Research, LLC

A trial comparing the efficacy and safety of insulin degludec/liraglutide and insulin degludec in subjects with type 2 diabetes. Subtitle: A 26-weeks randomised, parallel two-arm, double-blind, multi-centre, multinational, treat-to-target trial comparing fixed ratio combination of insulin degludec and liraglutide with insulin degludec in subjects with type 2 diabetes.

Waterbury : Chase Medical Research, LLC

The Effect of Dulaglutide on Major Cardiovascular Events in Patients with Type 2 Diabetes: Researching Cardiovascular Events with a Weekly Incretin in Diabetes.

Bridgeport :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Bridgeport :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Hartford :

Colesevelam Pediatric Type 2 Diabetes Mellitus Study

New Haven : Novo Nordisk Clinical Trial Call Center

Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes

New Haven : Research Site

Quantitative 18F-AV-133 PET Imaging in Subjects With Diabetes and Healthy Controls

Norwalk : 1245.25.10066 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Trumbull :

Comparison of TAK-875 to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes

Waterbury : 1276.10.11047 Boehringer Ingelheim Investigational Site

A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy

Waterbury : Novo Nordisk Clinical Trial Call Center Updated

A Long-term, Randomised, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

Waterbury : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)

Waterbury : Chase Medical Research, Llc

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Waterbury : Chase Medical Research, Llc

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Waterbury : 1245.25.10038 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Waterbury : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

Newark : Christiana Care Health Services, Inc

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Wilmington : Novo Nordisk Clinical Trial Call Center

Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes

Washington : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)

Washington : 1245.25.10068 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Washington : Investigational Site Number 840208

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Washington : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Washington : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

Aventura : South Florida Medical Research

A Phase 2B Repeat Dosing Clinical Trial of an Investigational Medication in Patients with Moderately Severe Diabetic Neuropathy

Clearwater : Clinical Research of West Florida

16 Million People in the U.S. Have Type II Diabetes. Are You One of Them?

Clearwater : Clinical Research of West Florida, Inc.

Do you have Type II Diabetes? Do you have difficulty in controlling your blood sugar levels on your current anti-diabetic medication?

Clearwater : Clinical Research of West Florida, Inc.

Type II Diabetes Research

Clearwater : Clinical Research of West Florida

When your TYPE 2 DIABETES is out of control, finding harmony is essential.

Coral Gables : Clinical Research of South Florida

Do you have Diabetes?

Hialeah : Eastern Research

CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes.

Miami : Pharmax Research Clinic, Inc.

Are you post-menopausal with low sexual desire and at risk for heart problems?

Miami : IMA Research

Clinical Trial to evaluate the safety and efficacy of a new medication in patients with Type II Diabetes with Inadequately Controlled Hypertension.

Miami : Pharmax Research Clinic, Inc.

Do you suffer from Gout and heart problems or diabetes?

Miami : Pharmax Research Clinic, Inc.

Patients between 18 and 90 years of age with Type 2 Diabetes and Moderate or Severe Chronic Kidney Disease

Miami : IMA Research

Study #2 Clinical Trial to evaluate the safety and efficacy of a new medication in patients with Type II Diabetes with Inadequately Controlled Hypertension.

Miami : Pharmax Research Clinic, Inc.

Uncontrolled Hypertension and Diabetes Type 2

Miramar : Comprehensive Clinical Development - Miramar, FL

Individuals 18 - 65 Diagnosed with Type 2 Diabetes, ITN # 11978

Miramar : Comprehensive Clinical Development - Miramar, FL

Individuals 18 to 70 years of age diagnosed with Type 2 Diabetes

Miramar : Comprehensive Clinical Development - Miramar, FL

Overweight Men and Women Including Type 2 Diabetics

Miramar : Comprehensive Clinical Development - Miramar, FL

Type 2 Diabetes

Miramar : Comprehensive Clinical Development - Miramar, FL

Type 2 Diabetes Mellitus

New Port Richey : Advanced Research Institute

A double-masked, randomized, placebo-controlled, multiple-ascending dose Phase 2 study to determine the tolerability, pharmokinetics, and pharmacodynamics of the GLP-1 receptor agonist HM11260C in adult subjects with type 2 diabetes mellitus on stable metformin therapy.

Ocala : Renstar Medical Research

Current treatment not controlling your Diabetes?

Ocala : Renstar Medical Research

Need help controlling your Type II Diabetes?

Ocala : Renstar Medical Research

Overweight with Type II Diabetes?

Ocala : Renstar Medical Research

Type II Diabetes that is not controlled by medication

Ocala : Renstar Medical Research

Uncontrolled Type II Diabetes`

St. Petersburg : Meridien Research

Type 2 Diabetes

St. Petersburg : Comprehensive Clinical Development - St. Petersburg, FL

Type II Diabetes

Tampa : Clinical Research of West Florida, Inc.

When your TYPE 2 DIABETES is out of control, finding harmony is essential.

West Palm Beach : Metabolic Research Institute, Inc.

A 22-week research study is evaluating if a new investigational insulin can provide effective and consistent blood sugar control in people with type 2 diabetes.

West Palm Beach : Palm Beach Research Center

Currently taking diabetic medication?

West Palm Beach : Metabolic Research Institute, Inc.

Do you have Type 2 Diabetes and are Taking Metformin Only?

West Palm Beach : Metabolic Research Institute, Inc.

Do you have Type 2 Diabetes? Are you on oral medications and not well controlled?

Aventura : Novo Nordisk Clinical Trial Call Center Updated

A Long-term, Randomised, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

Boca Raton :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Boca Raton : Investigational Site Number 840299

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Boca Raton : Boca Raton Clinical Research Associates, Inc.

Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes

Boynton Beach : Zasa Clinical Research

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Boynton Beach : Zasa Clinical Research

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Boynton Beach : Investigational Site Number 840285

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Boynton Beach :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Bradenton : Novo Nordisk Clinical Trial Call Center Updated

A Long-term, Randomised, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

Bradenton : Bradenton Research Center, Inc.

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Bradenton : Bradenton Research Center, Inc.

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Bradenton : Research Site

AMG 151 Amgen Protocol Number 20100761

Bradenton : 1245.25.10094 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Bradenton : Investigational Site Number 840221

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Bradenton :

Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes

Bradenton : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin Therapy

Brandon : PAB Clinical Research

Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus

Brandon : PAB Clinical Research

Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus

Brandon : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

Brooksville : Research Site

AMG 151 Amgen Protocol Number 20100761

Brooksville : 1245.25.10190 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Chipley : Family Care Associates Of Nw Fl

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Clearwater : Innovative Research Of West Florida, Inc

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Clearwater : Innovative Research Of West Florida, Inc

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Clearwater : Updated

A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities

Clearwater : Research Site

AMG 151 Amgen Protocol Number 20100761

Clearwater : 1245.25.10209 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Clearwater : Investigational Site Number 840233

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Clearwater :

Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes

Clearwater :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Cooper City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)

Cooper City : 1245.25.10212 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Coral Gables : Clinical Research Of South Florida

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Coral Gables : Clinical Research Of South Florida

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Coral Gables : Site 4

A Study to Evaluate Safety and Efficacy of TTP054 for 12 Weeks in Subjects With Type 2 Diabetes

Coral Gables : Investigational Site Number 840212

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Coral Gables : Investigational Site Number 840266

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Coral Gables :

Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes

Coral Gables : Clinical Research of South Florida

Safety and Efficacy of BGP-15 in Patients With Type 2 Diabetes Mellitus

Coral Gables : Clinical Therapeutics Corporation

Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes

Coral Gables :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Coral Springs :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Crystal River : Novo Nordisk Clinical Trial Call Center Updated

A Long-term, Randomised, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

Davie :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Daytona Beach : Call for Information (Investigational Site 0017)

A Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of MK-3102 to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy (MK-3102-024 AM3)

Deland : Avail Clinical Research, Llc

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Deland : Avail Clinical Research, Llc

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Deland : Updated

A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities

DeLand : Pfizer Investigational Site

Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus

Deland : Rankin, Bruce

Safety, Tolerability, Pharmacokinetics,Pharmacodynamics Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus

Delray Beach : 1245.25.10200 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Delray Beach :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Doral : In Vivo Clinical Research

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Doral : Call for Information (Investigational Site 0009)

A Study of MK-3102 in Participants With Type 2 Diabetes Mellitus With Chronic Kidney Disease or Kidney Failure on Dialysis (MK-3102-019 AM3)

Edgewater : Lexicon Investigational Site

Study to Evaluate the Pharmacodynamic and Pharmacokinetic Effects of LX4211 in Subjects With Type 2 Diabetes and Renal Impairment

Fleming Island :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Fort Lauderdale : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study Comparing the Effect of Dulaglutide With Liraglutide in Type 2 Diabetes

Fort Lauderdale : S&W Clinical Research

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Fort Lauderdale : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Fort Lauderdale : 1276.1.10026 Boehringer Ingelheim Investigational Site

Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes

Fort Myers : Research Site

AMG 151 Amgen Protocol Number 20100761

Fort Myers : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Ft Lauderdale :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Ft. Lauderdale : Call for Information (Investigational Site 0008) Updated

Addition of MK-3102 to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin (MK-3102-022 AM3)

Gainesville : Florida Research Network, LLC

Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus

Gainesville : Florida Research Network, LLC

Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus

Hallandale Beach : Call for Information (Investigational Site 0043) Updated

A Study to Assess Cardiovascular Outcomes Following Treatment With MK-3102 in Participants With Type 2 Diabetes Mellitus (MK-3102-018 AM5)

Hallandale Beach : 1245.25.10202 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Hialeah : Pfizer Investigational Site

A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy

Hialeah : Palm Springs Research Institute

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Hialeah : The Community Research Of South Florida

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Hialeah : International Research Associates, Llc

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Hialeah : International Research Associates, Llc

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Hialeah : The Community Research Of South Florida

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Hialeah : Palm Springs Research Institute

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Hialeah : Call for Information (Investigational Site 0039) Updated

A Study to Assess Cardiovascular Outcomes Following Treatment With MK-3102 in Participants With Type 2 Diabetes Mellitus (MK-3102-018 AM5)

Hialeah : 1245.25.10063 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Hialeah : Investigational Site Number 840204

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Hialeah :

Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes

Hialeah : Palm Springs Research Institute

Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes

Hialeah :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Hollywood : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)

Hollywood : 1245.25.10033 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Hollywood : Investigational Site Number 840248

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Jacksonville : Novo Nordisk Clinical Trial Call Center Updated

A Long-term, Randomised, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

Jacksonville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)

Jacksonville :

A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Sulfonylurea Alone or Sulfonylurea Plus Metformin Therapy

Jacksonville : 1245.25.10089 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Jacksonville :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Jacksonville : Investigational Site Number 840226

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Jacksonville : Investigational Site Number 840318

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Jacksonville :

Comparison of TAK-875 to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes

Jacksonville : Jacksonville Center for Clinical Research

Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus

Jacksonville : Southeast Clinical Research

Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes

Jacksonville : University Of Florida Endocrinology & Diabetes

Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes

Jacksonville : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin Therapy

Jupiter : Pfizer Investigational Site

A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy

Kissimmee : Novo Nordisk Clinical Trial Call Center Updated

A 26-week Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart BID and Insulin Degludec OD Plus Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin in Need of Treatment Intensification With Mealtime Insulin

Kissimmee : Central Florida Internists

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Kissimmee : Research Site

AMG 151 Amgen Protocol Number 20100761

Kissimmee : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy

Lake Mary :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Largo : Updated

A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities

Maitland : 1245.25.10168 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Melbourne : Novo Nordisk Clinical Trial Call Center Updated

A Long-term, Randomised, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

Melbourne :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Melbourne : Novo Nordisk Clinical Trial Call Center

Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes

Melbourne :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Melbourne : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy

Miami : Call for Information (Investigational Site 0001)

A Pharmacokinetic Study of MK-3102 in Participants With Impaired Hepatic Function (MK-3102-031)

Miami : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)

Miami :

A Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus Who Have Not Previously Received Anti-Hyperglycemic Therapy

Miami : Clinical Research Of Miami, Inc.

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Miami : Baptist Diabetes Associates, Pa

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Miami : Community Research Foundation, Inc.

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Miami : Pharmax Research Clinic, Inc.

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Miami : Apf Research, Llc

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Miami : Clinical Research Of Miami, Inc.

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Miami : Community Research Foundation, Inc.

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Miami : San Marcus Research Clinic, Inc.

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Miami : Baptist Diabetes Associates, Pa

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Miami : Medical Research Marseilles

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Miami : Call for Information (Investigational Site 0022)

A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM1)

Miami : Call for Information (Investigational Site 0031)

A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM1)

Miami : Call for Information (Investigational Site 0096) Updated

A Study to Assess Cardiovascular Outcomes Following Treatment With MK-3102 in Participants With Type 2 Diabetes Mellitus (MK-3102-018 AM5)

Miami : Call for Information (Investigational Site 0005) Updated

A Study to Assess Cardiovascular Outcomes Following Treatment With MK-3102 in Participants With Type 2 Diabetes Mellitus (MK-3102-018 AM5)

Miami : Call for Information (Investigational Site 0008) Updated

A Study to Assess Cardiovascular Outcomes Following Treatment With MK-3102 in Participants With Type 2 Diabetes Mellitus (MK-3102-018 AM5)

Miami : Call for Information (Investigational Site 0010) Updated

A Study to Assess Cardiovascular Outcomes Following Treatment With MK-3102 in Participants With Type 2 Diabetes Mellitus (MK-3102-018 AM5)

Miami : 1245.25.10039 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Miami : 1245.25.10184 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Miami :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Miami : Novartis Investigative Site

Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763

Miami : Investigational Site Number 840228

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Miami : Investigational Site Number 840238

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Miami : Investigational Site Number 840302

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Miami : Diabetes Research Institute

Effects of Pioglitazone on Igh-density Lipoprotein (HDL) Function in Persons With Diabetes

Miami : Novo Nordisk Clinical Trial Call Center

Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes

Miami : Pfizer Investigational Site

Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus

Miami : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

Miami : International Research Associates, Llc

Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes

Miami : Diabetes Research Institute

Safety Study of Mesenchymal Precursor Cells in Type 2 Diabetes

Miami : Novartis Investigative Site

Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) Assessment of LIK066 in Healthy Subjects and in Patients With Type 2 Diabetes Mellitus (T2DM)

Miami : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Study of How Dulaglutide Compares to Placebo in Participants With Type 2 Diabetes Who Are Also on Sulfonylurea Therapy (AWARD-8)

Miami :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Miami : Fl Clinical Research Institute, Llc

Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes

Miami : University Of Miami

Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes

Miami : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy

Miami : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin Therapy

Miami Beach : Newphase Clinical Trials, Inc.

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Miami Beach : Newphase Clinical Trials, Inc.

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Miami Beach : Investigational Site Number 840337

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Miami Beach : NextPhase Clinical Trials, Inc.

Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus

Miami Beach : NewPhase Clinical Trials, Inc.

Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus

Miami Gardens : Call for Information (Investigational Site 0037)

A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM1)

Miami Lakes : Call for Information (Investigational Site 0300)

A Study of the Safety and Efficacy of MK-0431A in Pediatric Participants With Type 2 Diabetes Mellitus (MK-0431A-170 AM1)

Miami Lakes : Call for Information (Investigational Site 0452) Updated

A Study of the Safety and Efficacy of MK-0431A XR in Pediatric Participants With Type 2 Diabetes Mellitus (MK-0431A-289 AM2)

Miami Springs : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)

Miami Springs : Ocean Blue Medical Research Center, Inc.

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Naples :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

New Port Richey : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)

New Port Richey : Suncoast Clinical Research, Inc.

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

New Port Richey : Suncoast Clinical Research, Inc.

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

New Port Richey : Investigational Site Number 840227

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

New Port Richey : Suncoast Clinical Research

Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus

New Port Richey : Suncoast Clinical Research

Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus

North Miami Beach : Investigational Site Number 840303

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

North Miami Beach :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Oakland Park : 1276.10.11009 Boehringer Ingelheim Investigational Site

A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy

Ocala : Novo Nordisk Clinical Trial Call Center Updated

A Long-term, Randomised, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

Ocala : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)

Ocala : Investigational Site Number 840225

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Ocala :

Comparison of TAK-875 to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes

Ocala :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Ocala : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin Therapy

Oldsmar : 1276.1.10024 Boehringer Ingelheim Investigational Site

Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes

Orlanda : Compass Research

Safety Study of Mesenchymal Precursor Cells in Type 2 Diabetes

Orlando : Florida Institute For Clinical Research, Llc

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Orlando : Florida Institute For Clinical Research, Llc

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Orlando : Compass Research, Llc

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Orlando : Call for Information (Investigational Site 0033)

A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM1)

Orlando : Call for Information (Investigational Site 0099) Updated

A Study to Assess Cardiovascular Outcomes Following Treatment With MK-3102 in Participants With Type 2 Diabetes Mellitus (MK-3102-018 AM5)

Orlando : Call for Information (Investigational Site 0003) Updated

Addition of MK-3102 to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin (MK-3102-022 AM3)

Orlando : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Observational Study to Understand Challenges Associated With Progression of Insulin Therapy in Type 2 Diabetes

Orlando : 1245.25.10123 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Orlando : 1245.25.10201 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Orlando :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Orlando : Investigational Site Number 840291

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Orlando : Investigational Site Number 840316

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Orlando :

Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes

Orlando : Arnold Palmer Hosp Ped Endocrinology Specialty Practice

Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes

Orlando : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin Therapy

Oviedo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study Comparing the Effect of Dulaglutide With Liraglutide in Type 2 Diabetes

Oviedo : Investigational Site Number 840216

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Palm Harbor : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)

Palm Harbor : Research Site

AMG 151 Amgen Protocol Number 20100761

Palm Harbor :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Palm Harbor : Investigational Site Number 840332

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Palm Harbor : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

Panama City :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Pembroke Pines : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)

Pembroke Pines : Michele A. Morrison Internal Medicine, Inc.

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Pembroke Pines : 1245.25.10025 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Pembroke Pines : 1245.25.10042 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Pembroke Pines : Investigational Site Number 840288

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Pembroke Pines :

Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes

Pembroke Pines :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Pineallas Park :

Pharmacokinetics, Pharmacodynamics and Safety of Alogliptin in Children, Adolescents and Adults With Type 2 Diabetes Mellitus

Pinellas : Bellingar, Bridget

Safety, Tolerability, Pharmacokinetics,Pharmacodynamics Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus

Plant City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

Plant City : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin Therapy

Ponte Vedra : Novo Nordisk Clinical Trial Call Center Updated

A Long-term, Randomised, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

Port Charlotte : 1245.25.10147 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Port Charlotte : Investigational Site Number 840325

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Port Charlotte : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

Port Orange : Site 5

A Study to Evaluate Safety and Efficacy of TTP054 for 12 Weeks in Subjects With Type 2 Diabetes

Port Orange : Call for Information (Investigational Site 0003)

A Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of MK-3102 to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy (MK-3102-024 AM3)

Port Orange : 1276.1.10027 Boehringer Ingelheim Investigational Site

Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes

Port Orange : Hamaidan, Ammar

Safety, Tolerability, Pharmacokinetics,Pharmacodynamics Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus

Port Orange : White, Alexander

Safety, Tolerability, Pharmacokinetics,Pharmacodynamics Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus

Saint Petersburg : 1245.25.10198 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Saint Petersburg : 1245.25.10203 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Sarasota :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

South Miami : South Miami Clinical Research, Llc

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

South Miami : Pfizer Investigational Site

Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus

South Miami : Regenerate Clinical Trials

Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus

South Miami : Regenerate Clinical Trials

Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus

St Petersburg :

A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Sulfonylurea Alone or Sulfonylurea Plus Metformin Therapy

St. Cloud :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

St. Petersburg : Research Site

AMG 151 Amgen Protocol Number 20100761

St. Petersburg :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

St. Petersburg : Investigational Site Number 840309

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

St. Petersburg : Comprehensive Clinical Development, Inc.

Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus

St. Petersburg :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Stuart :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Summerfield : Pfizer Investigational Site

A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy

Tallahassee : Wright, Nancy

Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes

Tampa : Updated

A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities

Tampa : Call for Information (Investigational Site 0056) Updated

A Study to Assess Cardiovascular Outcomes Following Treatment With MK-3102 in Participants With Type 2 Diabetes Mellitus (MK-3102-018 AM5)

Tampa : Research Site

AMG 151 Amgen Protocol Number 20100761

Tampa : 1245.25.10211 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Tampa :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Tampa :

Colesevelam Pediatric Type 2 Diabetes Mellitus Study

Tampa : Investigational Site Number 840251

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Tampa : Novo Nordisk Clinical Trial Call Center

Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes

Tampa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Study of How Dulaglutide Compares to Placebo in Participants With Type 2 Diabetes Who Are Also on Sulfonylurea Therapy (AWARD-8)

Tampa :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Trinity : Rodriguez, Daniel

Safety, Tolerability, Pharmacokinetics,Pharmacodynamics Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus

Wellington : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Observational Study to Understand Challenges Associated With Progression of Insulin Therapy in Type 2 Diabetes

West Palm Beach : Updated

A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities

West Palm Beach : Investigational Site Number 840339

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

West Palm Beach :

Comparison of TAK-875 to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes

West Palm Beach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

West Palm Beach : Metabolic Research Institute, Inc.

Safety and Efficacy of BGP-15 in Patients With Type 2 Diabetes Mellitus

Winter Haven : Clinical Research of Central Florida

Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus

Winter Haven : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

Winter Haven : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin Therapy

Winter Park : Research Site

AMG 151 Amgen Protocol Number 20100761

Blue Ridge : River Birch Research Alliance, LLC

Do you have Type II diabetes?

Blue Ridge : River Birch Research Alliance, LLC

Have you had a heart attack or unstable angina AND also have Type II diabetes?

Columbus : Southeast Regional Research Group

Type II Diabetes

Stockbridge : Clinical Research Atlanta

The Light Study

Atlanta :

A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin Alone

Atlanta :

A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Sulfonylurea Alone or Sulfonylurea Plus Metformin Therapy

Atlanta :

A Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus Who Have Not Previously Received Anti-Hyperglycemic Therapy

Atlanta : Call for Information (Investigational Site 0024)

A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM1)

Atlanta : Call for Information (Investigational Site 0027) Updated

A Study to Assess Cardiovascular Outcomes Following Treatment With MK-3102 in Participants With Type 2 Diabetes Mellitus (MK-3102-018 AM5)

Atlanta : Research Site

AMG 151 Amgen Protocol Number 20100761

Atlanta :

Colesevelam Pediatric Type 2 Diabetes Mellitus Study

Atlanta : Investigational Site Number 840245

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Atlanta : Novo Nordisk Clinical Trial Call Center

Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes

Atlanta : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Atlanta : Atlanta Diabetes Associates

FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)

Atlanta : Synergy Therapeutic Partners

Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus

Atlanta : Synergy Therapeutic Partners

Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus

Atlanta :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Atlanta : Novo Nordisk Clinical Trial Call Center

The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes

Atlanta : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy

Atlanta : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin Therapy

Augusta : Southern Clinical Research & Management

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Augusta :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Blue Ridge : River Birch Research Alliance, Llc

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Blue Ridge : River Birch Research Alliance, Llc

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Canton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Observational Study to Understand Challenges Associated With Progression of Insulin Therapy in Type 2 Diabetes

Columbus : Call for Information (Investigational Site 0022) Updated

A Study to Assess Cardiovascular Outcomes Following Treatment With MK-3102 in Participants With Type 2 Diabetes Mellitus (MK-3102-018 AM5)

Columbus : 1245.25.10174 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Columbus : Novo Nordisk Clinical Trial Call Center

Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes

Conyers :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Decatur :

Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes

Decatur : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Decatur : Atlanta Pharmaceutical Research

Safety and Efficacy of BGP-15 in Patients With Type 2 Diabetes Mellitus

Duluth : In-Quest Medical Research, Llc

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Duluth : In-Quest Medical Research, Llc

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Dunwoody : Novo Nordisk Clinical Trial Call Center Updated

A Long-term, Randomised, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

Dunwoody : Research Site

AMG 151 Amgen Protocol Number 20100761

Lawrenceville : Novo Nordisk Clinical Trial Call Center Updated

A Long-term, Randomised, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

Lawrenceville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Observational Study to Understand Challenges Associated With Progression of Insulin Therapy in Type 2 Diabetes

Lawrenceville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

Macon : Pfizer Investigational Site

A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy

Marietta : 1276.1.10023 Boehringer Ingelheim Investigational Site

Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes

Perry : Middle Georgia Drug Study Center, Llc

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Riverdale : 1245.25.10141 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Roswell : 1245.25.10067 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Roswell : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Roswell : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy

Roswell : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin Therapy

Savannah :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Stockbridge : Investigational Site Number 840323

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Tucker :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Honolulu : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)

Honolulu : Site 3

A Study to Evaluate Safety and Efficacy of TTP054 for 12 Weeks in Subjects With Type 2 Diabetes

Honolulu : 1245.25.10022 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Honolulu : Investigational Site Number 840236

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Honolulu : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

Honolulu : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin Therapy

Meridian : Advanced Clinical Research, ID

Do You Have Type 2 Diabetes & Struggle to Achieve Adequate Blood Sugar Levels?

Meridian : Advanced Clinical Research, ID

Hepatitis B Vaccine Clinical Research Study

Boise : GSK Investigational Site

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Engerix™-B in Adults With or Without Type 2 Diabetes Mellitus

Eagle : Choose To Lose

A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone

Eagle : CTL Research

Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus

Eagle : CTL Research

Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus

Idaho Falls : Call for Information (Investigational Site 0031) Updated

A Study to Assess Cardiovascular Outcomes Following Treatment With MK-3102 in Participants With Type 2 Diabetes Mellitus (MK-3102-018 AM5)

Idaho Falls : Investigational Site Number 840283

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Idaho Falls : Rocky Mountain Diabetes and Osteoporosis Center

Continuous Glucose Monitoring (CGM) in Subjects With Type 2 Diabetes

Idaho Falls : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Study of Human Regular U-500 Insulin in Adult Participants With Type 2 Diabetes

Lewiston : Valley Medical Center

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Lewiston : Valley Medical Center

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Meridian : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)

Meridian : Call for Information (Investigational Site 0002)

A Study to Assess the Safety and Efficacy of MK-3102 in Participants With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control (MK-3102-011)

Meridian : Call for Information (Investigational Site 0006) Updated

Addition of MK-3102 to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin (MK-3102-022 AM3)

Meridian : Research Site

AMG 151 Amgen Protocol Number 20100761

Meridian : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy

Nampa :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Pocatello : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Addison : Biofortis Clinical Research

Do you have uncontrolled Type 2 Diabetes?

Gurnee : Clinical Investigation Specialists, Inc. Updated

Diabetes can be unpredictable.

Gurnee : Clinical Investigation Specialists, Inc. Updated

Do you have Type 2 Diabetes?

Arlington Heights : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin Therapy

Aurora :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Burr Ridge :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Chicago : 1276.10.11027 Boehringer Ingelheim Investigational Site

A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy

Chicago : Pfizer Investigational Site

A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy

Chicago : Cedar-Crosse Research Center

A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone

Chicago :

A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin Alone

Chicago :

A Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus Who Have Not Previously Received Anti-Hyperglycemic Therapy

Chicago : Cedar Crosse Research Center

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Chicago : Cedar Crosse Research Center

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Chicago : James R. Herron, Md, Ltd

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Chicago : Call for Information (Investigational Site 0004)

A Study of MK-3102 in Participants With Type 2 Diabetes Mellitus With Chronic Kidney Disease or Kidney Failure on Dialysis (MK-3102-019 AM3)

Chicago : Updated

A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities

Chicago : 1245.25.10097 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Chicago :

Colesevelam Pediatric Type 2 Diabetes Mellitus Study

Chicago : Investigational Site Number 840278

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Chicago : Investigational Site Number 840320

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Chicago :

Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes

Chicago : Cedar-Crosse Research Center

Evaluate Safety of Technosphere® Insulin Inhalation Powder (TI Inhalation Powder) on Diabetic Subjects With Mild Obstructive Pulmonary Disease

Chicago : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Chicago : Northwestern University Medical Center

Glargine Dosing in Hospitalized Patients With Type 2 Diabetes and Renal Insufficiency

Chicago : Rush University Medical Center

Glargine Dosing in Hospitalized Patients With Type 2 Diabetes and Renal Insufficiency

Chicago : John Stroger Hospital of Cook County

Outpatient Discharge Therapy With Saxagliptin+MetforminXR vs GlipizideXL for Type 2 Diabetes With Severe Hyperglycemia

Chicago : Cedar-Crosse Research Center

Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus

Chicago : Cedar-Crosse Research Center

Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus

Chicago : ICCT Research International, Inc.

Safety and Efficacy of BGP-15 in Patients With Type 2 Diabetes Mellitus

Chicago :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Chicago : Alianza Research, Inc.

Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes

Chicago : University of Chicago Hospitals

The Effects of Nebivolol on Aortic Impedance Parameters in Type 2 Diabetes (The Effort Trial)

Crystal Lake : Novo Nordisk Clinical Trial Call Center Updated

A Long-term, Randomised, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

Crystal Lake : Midwest Endocrinology, Llc

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Crystal Lake : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Observational Study to Understand Challenges Associated With Progression of Insulin Therapy in Type 2 Diabetes

Evergreen Park : Pfizer Investigational Site

A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy

Gurnee : Novo Nordisk Clinical Trial Call Center

The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes

Gurnee : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy

Hines : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Jerseyville :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

LaGrange :

Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes

LaGrange :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Maywood : Loyola University Hospital

Glargine Dosing in Hospitalized Patients With Type 2 Diabetes and Renal Insufficiency

O?Fallon : So. Illinois Clin Res Ctr @ Div Of Kevin L Pritchett Md, Pc

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

O?Fallon : So. Illinois Clin Res Ctr @ Div Of Kevin L Pritchett Md, Pc

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Olympia Fields : St. James Ctr For Diabetes

Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes

Peoria : Pfizer Investigational Site

A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy

Quincy :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Springfield : Springfield Diabetes And Endocrine Center

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Springfield : Springfield Diabetes And Endocrine Center

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Springfield :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Springfield : Investigational Site Number 840276

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Springfield : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Vernon Hills : Call for Information (Investigational Site 0030) Updated

A Study to Assess Cardiovascular Outcomes Following Treatment With MK-3102 in Participants With Type 2 Diabetes Mellitus (MK-3102-018 AM5)

Avon : Novo Nordisk Clinical Trial Call Center Updated

A 26-week Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart BID and Insulin Degludec OD Plus Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin in Need of Treatment Intensification With Mealtime Insulin

Avon :

A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin Alone

Avon :

A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Sulfonylurea Alone or Sulfonylurea Plus Metformin Therapy

Avon :

A Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus Who Have Not Previously Received Anti-Hyperglycemic Therapy

Avon : American Health Network Of Indiana Llc

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Avon : American Health Network Of Indiana Llc

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Avon : Investigational Site Number 840314

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Avon :

Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes

Avon :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Elkhart :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Elwood : Pfizer Investigational Site

A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy

Evansville : 1245.25.10116 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Evansville :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Franklin : American Health Network Of In Llc

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Franklin : American Health Network Of In Llc

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Franklin : Investigational Site Number 840317

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Gary : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Greenfield :

Comparison of TAK-875 to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes

Greenfield :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Greenfield : Novo Nordisk Clinical Trial Call Center

The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes

Indianapolis : Site 17

A Study to Evaluate Safety and Efficacy of TTP054 for 12 Weeks in Subjects With Type 2 Diabetes

Indianapolis : Research Site

AMG 151 Amgen Protocol Number 20100761

Indianapolis :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Indianapolis : Indiana Clinical Research Center

Cooperation of Insulin and GLP-1 on Myocardial Glucose Uptake

Indianapolis : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Indianapolis : Call for Information (Investigational Site 0003)

Gut Hormone Profiling in Obese Patients With Type 2 Diabetes (MK-0000-134 AM2)

Indianapolis : Research Site

Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes

Indianapolis : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin Therapy

Michigan City : Novo Nordisk Clinical Trial Call Center Updated

A Long-term, Randomised, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

Michigan City : Laporte County Institute For Clinical Research, Inc.

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Michigan City : Laporte County Institute For Clinical Research, Inc.

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Michigan City : LaPorte County Institute for Clinical Research

Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus

Michigan City : LaPorte County Institute for Clinical Research

Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus

Mishawaka : GSK Investigational Site

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Engerix™-B in Adults With or Without Type 2 Diabetes Mellitus

Muncie : American Health Network Of In Llc

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Muncie : American Health Network Of In Llc

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Muncie :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Muncie :

Comparison of TAK-875 to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes

Muncie :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Munster : Cardiovascular Research Of Northwest Indiana, Llc

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Munster :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

New Albany :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Valparaiso : Call for Information (Investigational Site 0063) Updated

A Study to Assess Cardiovascular Outcomes Following Treatment With MK-3102 in Participants With Type 2 Diabetes Mellitus (MK-3102-018 AM5)

Valparaiso : 1245.25.10206 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Ames :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Council Bluffs : Call for Information (Investigational Site 0060) Updated

A Study to Assess Cardiovascular Outcomes Following Treatment With MK-3102 in Participants With Type 2 Diabetes Mellitus (MK-3102-018 AM5)

Council Bluffs :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Des Moines : Investigational Site Number 840214

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Des Moines : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Iowa City : Novo Nordisk Clinical Trial Call Center

Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes

Wichita : Wichita Clinic, PA

Do you have Type 2 Diabetes?

Wichita : Via Christi Research

Investigate safety of study drug to treat Type 2 Diabetes and high cardiovascular risks.

Wichita : Via Christi Research

Study of TAK-875 in Adults with Type 2 Diabetes & Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Wichita : Via Christi Research

Study to Evaluate Cardiovascular Outcomes in Volunteers with Type 2 Diabetes with ITCA 650 Implant

Kansas City :

Colesevelam Pediatric Type 2 Diabetes Mellitus Study

Kansas City : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Overland Park : Investigational Site Number 840232

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Overland Park : Investigational Site Number 840001

Evaluation of the Blood Levels of the Drug (Lixisenatide), the Plasma Glucose Levels and Safety in Paediatric and Adult Patients With Type 2 Diabetes

Shawnee Mission :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Topeka : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)

Topeka : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study Comparing the Effect of Dulaglutide With Liraglutide in Type 2 Diabetes

Topeka : Investigational Site Number 840287

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Topeka :

Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes

Topeka : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

Topeka : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Study of How Dulaglutide Compares to Placebo in Participants With Type 2 Diabetes Who Are Also on Sulfonylurea Therapy (AWARD-8)

Topeka :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Wichita : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)

Wichita : 1245.25.10021 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Wichita : GSK Investigational Site

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Engerix™-B in Adults With or Without Type 2 Diabetes Mellitus

Wichita : Research Site

Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes

Crestview Hills : Community Research

Type II Diabetes Research

Crestview Hills : Community Research

Type-II Diabetes

Crestview Hills : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Crestview Hills : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy

Elizabethtown :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Elizabethtown :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Lexington : Updated

A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities

Lexington : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Observational Study to Understand Challenges Associated With Progression of Insulin Therapy in Type 2 Diabetes

Lexington : 1245.25.10186 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Lexington :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Lexington : Investigational Site Number 840344

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Lexington :

Comparison of TAK-875 to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes

Lexington : Pfizer Investigational Site

Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus

Lexington : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

Lexington : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Study of How Dulaglutide Compares to Placebo in Participants With Type 2 Diabetes Who Are Also on Sulfonylurea Therapy (AWARD-8)

Lexington : Novo Nordisk Clinical Trial Call Center

The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes

Lexington : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin Therapy

Lexington : VA Medical Center - Lexington 596

Veterans Inpatient Insulin Study and Transition to Outpatient Therapy

Louisville : Novo Nordisk Clinical Trial Call Center Updated

A Long-term, Randomised, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

Louisville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study Comparing the Effect of Dulaglutide With Liraglutide in Type 2 Diabetes

Louisville : Site 7

A Study to Evaluate Safety and Efficacy of TTP054 for 12 Weeks in Subjects With Type 2 Diabetes

Louisville : 1245.25.10109 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Louisville : Investigational Site Number 840003

Evaluation of the Blood Levels of the Drug (Lixisenatide), the Plasma Glucose Levels and Safety in Paediatric and Adult Patients With Type 2 Diabetes

Louisville : Pfizer Investigational Site

Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus

Louisville :

Pharmacokinetics, Pharmacodynamics and Safety of Alogliptin in Children, Adolescents and Adults With Type 2 Diabetes Mellitus

Louisville : L-MARC Research Center

Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus

Madisonville :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Madisonville : 1218.74.01218 Boehringer Ingelheim Investigational Site

CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes

Mount Sterling : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Murray : Investigational Site Number 840231

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Owensboro : Updated

A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities

Owensboro :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Owensboro :

Comparison of TAK-875 to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes

Paducah : Pfizer Investigational Site

A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy

Paducah : 1245.25.10005 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Alexandria : Alexandria Cardiology Clinic

A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone

Alexandria :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Alexandria : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Baton Rouge : Medical Development Centers, Llc

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Baton Rouge : Medical Development Centers, Llc

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Baton Rouge : Woman's Hospital

Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)

Baton Rouge : Pennington Biomedical Research Center

Safety Study of Mesenchymal Precursor Cells in Type 2 Diabetes

Eunice : Horizon Research Group of Opelousas

Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus

Lafayette : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)

Marrero :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Metairie : Clinical Trials Management, LLC

A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone

Metairie : Omega Clinical Research, Llc

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Metairie : Crescent City Clinical Research Center

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Metairie : Research Site

AMG 151 Amgen Protocol Number 20100761

Metairie : Investigational Site Number 840348

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Metairie : Clinical Trials Management, LLC

Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus

Metairie : Novo Nordisk Clinical Trial Call Center

The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes

Monroe : Novo Nordisk Clinical Trial Call Center Updated

A Long-term, Randomised, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

Natchitoches :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

New Orleans : Novo Nordisk Clinical Trial Call Center Updated

A Long-term, Randomised, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

New Orleans : 1245.25.10020 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

New Orleans :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

New Orleans : Investigational Site Number 840290

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

New Orleans : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

New Orleans : Tulane University Health Sciences Center

Safety and Efficacy of EndoBarrier in Subjects With Type 2 Diabetes Who Are Obese

New Orleans : Tulane University Medical Center

Safety Study of Mesenchymal Precursor Cells in Type 2 Diabetes

Salt Lake City : Wasatch Clinical Research

Safety Study of Mesenchymal Precursor Cells in Type 2 Diabetes

Sherveport :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Shreveport : Pfizer Investigational Site

A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy

Shreveport : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study Comparing the Effect of Dulaglutide With Liraglutide in Type 2 Diabetes

Shreveport : Call for Information (Investigational Site 0034) Updated

A Study to Assess Cardiovascular Outcomes Following Treatment With MK-3102 in Participants With Type 2 Diabetes Mellitus (MK-3102-018 AM5)

Shreveport : LSU Shreveport

PK Study of Dapagliflozin in Pediatric Subjects With T2DM

Slidell : Novo Nordisk Clinical Trial Call Center Updated

A 26-week Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart BID and Insulin Degludec OD Plus Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin in Need of Treatment Intensification With Mealtime Insulin

Slidell : Louisiana Heart Center

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Slidell : Louisiana Heart Center

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Slidell :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Auburn : Site 8

A Study to Evaluate Safety and Efficacy of TTP054 for 12 Weeks in Subjects With Type 2 Diabetes

Auburn : 1245.25.10012 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Auburn : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Bangor : 1276.10.11001 Boehringer Ingelheim Investigational Site

A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy

Biddeford :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Portland : Call for Information (Investigational Site 0012)

A Study of the Safety and Efficacy of MK-0431A in Pediatric Participants With Type 2 Diabetes Mellitus (MK-0431A-170 AM1)

Portland :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Portland : Call for Information (Investigational Site 0009)

Study to Assess Safety & Efficacy of Sitagliptin as Initial Monotherapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants (MK-0431-083 AM1)

Rockport : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)

Rockport :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Baltimore : Spectrum Clinical Research, Inc.

A Safety and Efficacy Study to Evaluate the Potential of Aleglitazar to Reduce Cardiovascular Risk in Coronary Heart Disease (CHD) Patients With a Recent Acute Coronary Syndrome (ACS) Event and Type 2 Diabetes Mellitus (T2D)

Baltimore : Spectrum Clinical Research, Inc.

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Baltimore : Spectrum Clinical Research, Inc.

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Towson : Spectrum Clinical Research, Inc.

A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes

Balitmore :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Baltimore : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)

Baltimore : Overlea Personal Physicians

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Baltimore : Overlea Personal Physicians

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Baltimore :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Baltimore :

Colesevelam Pediatric Type 2 Diabetes Mellitus Study

Baltimore : Novo Nordisk Clinical Trial Call Center

Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes

Baltimore : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Baltimore :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Bethesda : Research Site

AMG 151 Amgen Protocol Number 20100761

College Park : 1245.25.10134 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Hyattsville :

Comparison of TAK-875 to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes

Hyattsville : MedStar Health Research Institute

Safety and Efficacy of EndoBarrier in Subjects With Type 2 Diabetes Who Are Obese

Oxon Hill : Call for Information (Investigational Site 0045) Updated

A Study to Assess Cardiovascular Outcomes Following Treatment With MK-3102 in Participants With Type 2 Diabetes Mellitus (MK-3102-018 AM5)

Oxon Hill :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Oxon Hill :

Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes

Oxon Hill : MD Medical Research

Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus

Oxon Hill : MD Medical Research

Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus

Randallstown : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Rockville : Novo Nordisk Clinical Trial Call Center Updated

A 26-week Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart BID and Insulin Degludec OD Plus Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin in Need of Treatment Intensification With Mealtime Insulin

Rockville : Pfizer Investigational Site

A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy

Rockville :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Rockville : Investigational Site Number 840301

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Rockville : Investigational Site Number 840017

Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients

Rockville : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Rockville : Novo Nordisk Clinical Trial Call Center

The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes

Rockville : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy

Rockville : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin Therapy

Silver Spring : Alternative Primary Care

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Silver Spring : Alternative Primary Care

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Towson : 1245.25.10210 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Towson : IRC Clinics, Inc

Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus

Towson : IRC Clinics, Inc

Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus

Boston : Joslin Diabetes Center

Are you having gastric bypass surgery? Do you have type 2 diabetes?

Boston : Brigham and Women's Hospital and Joslin Diabetes Center

Do you have type 2 diabetes and are ready to stop struggling with your weight? Would you consider weight loss surgery OR be willing to participate in an intensive lifestyle program?

Boston : Joslin Diabetes Center

SUGAR MGH Study: Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans

Boston : Joslin Diabetes Center

The Brain and Nutrition Study

Boston : Joslin Diabetes Center

The Effects of Type 2 Diabetes on Brain Function Study

Boston : Joslin Diabetes Center

The SIMPLE Study: Simplified Insulin Management protocol using Lantus in Elderly

Boston : Joslin Diabetes Center

The SIMPLE Study: Simplified Insulin Management protocol using Lantus in Elderly

Brockton : Beacon Clinical Research

Type 2 diabetes

Haverhill : ActivMed Practices & Research, Inc.

Are you overweight? Do you also have Type 2 Diabetes or Heart Disease?

Haverhill : ActivMed Practices & Research, Inc.

Are Your Blood Sugar Numbers Out Of Control?

Haverhill : ActivMed Practices & Research, Inc.

Do you or a loved one have Type II Diabetes?

Haverhill : ActivMed Practices & Research, Inc.

Would you be interested in taking part in a type 2 diabetes research study?

Watertown : MedVadis Research Corporation

A research study to evaluate the efficacy and safety of the co-administration of sitagliptin and atorvastatin in patients with type 2 diabetes with inadequate glycemic control on metformin monotherapy

Boston :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Boston : Joslin Diabetes Center

FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)

Brookline : Neurocare Center For Research

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Brookline : Neurocare, Inc.

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Fall River : Genesis Clinical Research, Llc

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Fall River :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Fall River : Investigational Site Number 840289

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Haverhill : Investigational Site Number 840253

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Haverhill : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Study of How Dulaglutide Compares to Placebo in Participants With Type 2 Diabetes Who Are Also on Sulfonylurea Therapy (AWARD-8)

Haverhill : Novo Nordisk Clinical Trial Call Center

The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes

Hyannis :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Newton : Infosphere Clinical Research, Inc.

Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes

Newton : Clinical Research Of Miami, Inc.

Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes

Springfield : 1245.25.10064 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Springfield :

Colesevelam Pediatric Type 2 Diabetes Mellitus Study

Watertown : Atlantic Clinical Trials, Llc

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Watertown : Atlantic Clinical Trials, Llc

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Watertown : 1245.25.10051 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Worcester : Novo Nordisk Clinical Trial Call Center

Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes

Alpena :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Alpena : Endeavor Medical Research, PLC

Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus

Ann Arbor : The University of Michigan Health System

Evaluation of Exenatide in Patients With Diabetic Neuropathy

Ann Arbor : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Battle Creek : Associated Internal Medicine Specialists, P.C.

Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus

Battle Creek : Associated Internal Medicine Specialists, P.C.

Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus

Bloomfield Hills : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Bridgman :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Dearborn : Call for Information (Investigational Site 0054) Updated

A Study to Assess Cardiovascular Outcomes Following Treatment With MK-3102 in Participants With Type 2 Diabetes Mellitus (MK-3102-018 AM5)

Dearborn : 1245.25.10071 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Dearborn :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Dearborn : Research Site

Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes

Dearborn : Alzohaili Medical Consultants

Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes

Detroit : Call for Information (Investigational Site 0019)

A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM1)

Detroit : Call for Information (Investigational Site 0002) Updated

A Study to Assess Cardiovascular Outcomes Following Treatment With MK-3102 in Participants With Type 2 Diabetes Mellitus (MK-3102-018 AM5)

Detroit :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Detroit : Novo Nordisk Clinical Trial Call Center

Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes

Detroit : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Detroit : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

Flint : Pfizer Investigational Site

A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy

Flint : 1245.25.10013 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Flint :

Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes

Flint :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Grand Rapids : Jeffrey Vanwingen, Md

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Grand Rapids : Jeffrey Vanwingen, Md

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Kalamazoo : Call for Information (Investigational Site 0012) Updated

Addition of MK-3102 to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin (MK-3102-022 AM3)

Kalamazoo :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Kalamazoo : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin Therapy

Madison Heights : Investigational Site Number 840270

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Muskegon :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Novi : Providence Park Clinical Research

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Novi : Providence Park Clinical Research

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Petoskey : 1245.25.10107 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Royal Oak : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study Comparing the Effect of Dulaglutide With Liraglutide in Type 2 Diabetes

Saginaw : Saginaw Valley Medical Research Group, Llc

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Saginaw : Saginaw Valley Medical Research Group, Llc

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Saginaw :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Saginaw :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

St. Clair Shores : Kmed Research

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

St. Clair Shores : Kmed Research

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Sterling Heights : 1276.10.11048 Boehringer Ingelheim Investigational Site

A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy

Troy :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Troy :

Comparison of TAK-875 to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes

Troy : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy

Troy : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin Therapy

Warren :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Edina : Radiant Research - Minneapolis

Diabetes Research Study

Edina : Radiant Research - Minneapolis

Type 2 Diabetes Research Study

Edina : Radiant Research - Minneapolis

Type II Diabetes Research

Bloomington : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Duluth :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Duluth : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Eagan : 1245.25.10030 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Minneapolis : 1245.25.10028 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Minneapolis :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Minneapolis : International Diabetes Center

Continuous Glucose Monitoring Evaluation of Exenatide Twice Daily Versus Insulin Glargine

Minneapolis : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Minneapolis : International Diabetes Center

FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)

Minneapolis : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

Minneapolis : International Diabetes Center

The Impact of Food on Blood Sugar in People With Type 2 Diabetes

Rochester : Mayo Clinic

Effects of Hyperglycemia on Myocardial Perfusion in Humans With and Without Type 2 Diabetes

Saint Paul : Pfizer Investigational Site

Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus

St. Cloud :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

St. Paul :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Biloxi : The Center For Clinical Trials

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Biloxi : The Center For Clinical Trials

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Jackson : Phillips Medical Services, Pllc

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Jackson :

Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes

Olive Branch : Call for Information (Investigational Site 0064) Updated

A Study to Assess Cardiovascular Outcomes Following Treatment With MK-3102 in Participants With Type 2 Diabetes Mellitus (MK-3102-018 AM5)

Picayune : 1245.25.10176 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Picayune :

Comparison of TAK-875 to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes

Hazelwood : Healthcare Research Network

Do you have Diabetic Foot Pain? Are you 18+ years old? If so, you may qualify for our study! Call us today to find out more information.

Kansas City : Dynamic Clinical Research, Inc.

A 16-week, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to compare the safety and efficacy of Starlix (nateglinide) vs. placebo in patients with type 2 diabetes who are inadequately controlled with basal insulin glargine in combination with metformin and/or thiazolidinedione (pioglitazone or rosiglitazone)

Kansas City : Dynamic Clinical Research, Inc.

A Multi-center, Randomized, Open-label, Active Controlled, Parallel Arm Study to Compare the Efficacy of 12 Weeks of Treatment with Vildagliptin 100mg, qd to Thiazolidinedione (TZD) as Add-on Therapy in Patients with type 2 Diabetes Inadequately Controlled with Metformin Monotherapy in a Community-based Practice Setting

Kansas City : Dybedal Clinical Research Center

Title: Protocol MB102077: A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Subjects with Type 2 Diabetes with Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) and an Additional Antihypertensive Medication

St. Louis : Washington University in St. Louis - Center for Clinical Studies

A Washington University Vitamin D Research Study Seeks Volunteers with Type 2 Diabetes.

St. Louis : Washington University in St. Louis - Center for Clinical Studies

Are you down in the dumps with your diabetes?

St. Louis : Radiant Research - St. Louis

Diabetes Research

St. Louis : Washington University in St. Louis - Center for Clinical Studies

Do you have type 2 diabetes and coronary artery disease?

St. Louis : Washington University in St. Louis - Center for Clinical Studies

Pre-diabetes: Are you at risk?

St. Louis : Washington University in St. Louis - Center for Clinical Studies

Type 2 diabetes study seeks participants 10 – 25 years old.

Chesterfield : Novo Nordisk Clinical Trial Call Center Updated

A Long-term, Randomised, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

Chesterfield : 1245.25.10011 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Chesterfield :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Chesterfield : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Chesterfield : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy

Columbia : 1245.25.10112 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Columbia : Novo Nordisk Clinical Trial Call Center

Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes

Columbia : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

Jefferson City : Jefferson City Medical Group

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Jefferson City : Jefferson City Medical Group

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Kansas City : Pfizer Investigational Site

A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy

Kansas City : Kcumb Dybedal Clinical Research Center

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Kansas City : Call for Information (Investigational Site 0001)

A Study to Assess the Pharmacokinetics and the Ability for Pediatric Participants With Type 2 Diabetes to Swallow MK-0431A XR Tablets (MK-0431A-296)

Kansas City : 1245.25.10163 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Kansas City :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Kansas City : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Kansas City : Kansas City Children's/Childrens Mercy

PK Study of Dapagliflozin in Pediatric Subjects With T2DM

Kansas City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

Kansas City : The Center for Pharmaceutical Research, P.C.

Safety and Efficacy of BGP-15 in Patients With Type 2 Diabetes Mellitus

Marionville :

A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin Alone

Saint Louis : Novo Nordisk Clinical Trial Call Center Updated

A Long-term, Randomised, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

Springfield : Novo Nordisk Clinical Trial Call Center Updated

A Long-term, Randomised, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

St Louis : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

St Louis : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Study of How Dulaglutide Compares to Placebo in Participants With Type 2 Diabetes Who Are Also on Sulfonylurea Therapy (AWARD-8)

St Peters :

A Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus Who Have Not Previously Received Anti-Hyperglycemic Therapy

St. Charles : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy

St. Charles : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin Therapy

St. Joseph :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

St. Louis : Novo Nordisk Clinical Trial Call Center Updated

A Long-term, Randomised, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

St. Louis : St. Louis Center For Clinical Research

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

St. Louis : Research Site

AMG 151 Amgen Protocol Number 20100761

St. Louis :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

St. Louis :

Comparison of TAK-875 to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes

St. Louis : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

St. Louis : Washington University

FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)

St. Louis : Mercy Health Research

Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes

St. Louis :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

St. Louis : St. Louis Children'S Hospital

Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes

Billings : Montana Health Research Institute, Inc.

Do you have diabetes?

Billings : Billings Clinic Research Center

Evaluate Safety of Technosphere® Insulin Inhalation Powder (TI Inhalation Powder) on Diabetic Subjects With Mild Obstructive Pulmonary Disease

Billings : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Billings : Billings Clinic

Safety and Efficacy of EndoBarrier in Subjects With Type 2 Diabetes Who Are Obese

Billings : Billings Clinical Research Center

Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes

Butte : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Butte : Big Sky Clinical Research

Safety Study of Mesenchymal Precursor Cells in Type 2 Diabetes

Great Falls : 1245.25.10191 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Great Falls : 1245.25.10148 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Great Falls :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Kalispell : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

Kansas City : Kcumb Dybedal Clinical Research Center

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Missoula : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Bellevue : Updated

A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities

Fremont : Clinical Research Advantage

Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes

Lincoln : Pfizer Investigational Site

A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy

Lincoln : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)

Lincoln : Call for Information (Investigational Site 0025)

A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM1)

Lincoln : Call for Information (Investigational Site 0072) Updated

A Study to Assess Cardiovascular Outcomes Following Treatment With MK-3102 in Participants With Type 2 Diabetes Mellitus (MK-3102-018 AM5)

Lincoln : Investigational Site Number 840258

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Lincoln : Novartis Investigative Site

Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) Assessment of LIK066 in Healthy Subjects and in Patients With Type 2 Diabetes Mellitus (T2DM)

North Platte : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Observational Study to Understand Challenges Associated With Progression of Insulin Therapy in Type 2 Diabetes

Omaha : Novo Nordisk Clinical Trial Call Center Updated

A Long-term, Randomised, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

Omaha : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)

Omaha : 1245.25.10034 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Omaha : 1245.25.10205 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Omaha :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Omaha : Investigational Site Number 840210

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Omaha : Investigational Site Number 840263

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Omaha : Investigational Site Number 840300

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Omaha :

Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes

Omaha : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Omaha : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

Omaha : Novo Nordisk Clinical Trial Call Center

The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes

Omaha : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin Therapy

Las Vegas : AB Clinical Trials

Do you have Type II Diabetes?

Henderson : Clinical Research Advantage

A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone

Henderson : Clin Research Advantage, Inc. James Meli, Do Family Pracice

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Henderson : Clin Research Advantage, Inc. James Meli, Do Family Pracice

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Henderson : Desert Endocrinology Clinical Research Center-Henderson

Safety Study of Mesenchymal Precursor Cells in Type 2 Diabetes

Henderson : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin Therapy

Las Vegas : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study Comparing the Effect of Dulaglutide With Liraglutide in Type 2 Diabetes

Las Vegas : Independent Clinical Researchers@ Wolfson Medical Center

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Las Vegas : Ab Clinical Trials

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Las Vegas : Clinical Research Advantage, Inc.

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Las Vegas : Office Of Ted Thorp, Md

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Las Vegas : Palm Medical Research Center

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Las Vegas : Clinical Research Advantage, Inc.

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Las Vegas : Independent Clinical Researchers@ Wolfson Medical Center

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Las Vegas : Office Of Ted Thorp, Md

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Las Vegas : Palm Medical Research Center

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Las Vegas : Updated

A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities

Las Vegas : Site 9

A Study to Evaluate Safety and Efficacy of TTP054 for 12 Weeks in Subjects With Type 2 Diabetes

Las Vegas :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Las Vegas : Investigational Site Number 840256

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Las Vegas : Investigational Site Number 840349

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Las Vegas : Investigational Site Number 840201

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Las Vegas : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Las Vegas : Nevada Alliance Against Diabetes

Safety and Efficacy of BGP-15 in Patients With Type 2 Diabetes Mellitus

Las Vegas : Clinical Research Advantage, Inc.

Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes

Las Vegas : 1276.1.10007 Boehringer Ingelheim Investigational Site

Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes

Las Vegas : Alliance Against Diabetes/AAD Clinical Research

Safety Study of Mesenchymal Precursor Cells in Type 2 Diabetes

Las Vegas :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Las Vegas : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin Therapy

Reno : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Observational Study to Understand Challenges Associated With Progression of Insulin Therapy in Type 2 Diabetes

Reno : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Reno : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin Therapy

Newington : ActivMed Practices & Research, Inc. NH Updated

Are You Struggling To Manage Your Type 2 Diabetes?

Newington : ActivMed Practices & Research, Inc. NH

Would you be interested in taking part in a type 2 diabetes research study?

Nashua : Novo Nordisk Clinical Trial Call Center Updated

A Long-term, Randomised, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

Nashua : Call for Information (Investigational Site 0038)

A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM1)

Nashua : Call for Information (Investigational Site 0014) Updated

A Study to Assess Cardiovascular Outcomes Following Treatment With MK-3102 in Participants With Type 2 Diabetes Mellitus (MK-3102-018 AM5)

Nashua : Joslin Diabetes Center Affiliate Of Snhmc

Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes

Nashua :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Nashua : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy

Nashua : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin Therapy

Newington : Novo Nordisk Clinical Trial Call Center

The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes

Edison : Anderson & Collins Clinical Research, Inc.

At Risk for Type 2 DIABETES?

Toms River : Physicians Research Center, LLC

6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus both in combination with oral antihyperglycemic drug in Patients with Type 2 Diabetes Mellitus with a 6 month Safety Extension Period.

Toms River : Physicians Research Center, LLC

The effect of insulin degludec in combination with liraglutide and metformin in subjects with type 2 diabetes qualifying for treatment intensification

Berlin : Comprehensive Clinical Research

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Berlin : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin Therapy

Blackwood : 1245.25.10194 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Brick : Libra Clinical Research Associates

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Bridgewater :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Camden :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Camden : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

Elizabeth : Central Jersey Medical Research Center

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Elizabeth : Call for Information (Investigational Site 0017)

A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM1)

Elizabeth : Call for Information (Investigational Site 0001) Updated

A Study to Assess Cardiovascular Outcomes Following Treatment With MK-3102 in Participants With Type 2 Diabetes Mellitus (MK-3102-018 AM5)

Elizabeth :

Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes

Elizabeth :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Flemington : 1245.25.10014 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Flemington : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin Therapy

Hackensack : Novo Nordisk Clinical Trial Call Center

Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes

Haddon Heights :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Haddon Heights :

Comparison of TAK-875 to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes

Haddon Heights : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Haddon Heights :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Hamilton : Investigational Site Number 840306

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Hamilton : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Hamilton : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin Therapy

Lawrenceville : Novo Nordisk Clinical Trial Call Center Updated

A 26-week Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart BID and Insulin Degludec OD Plus Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin in Need of Treatment Intensification With Mealtime Insulin

Lawrenceville : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin Therapy

Linden :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Livingston : Novo Nordisk Clinical Trial Call Center

Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes

Lyons : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Margate : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Mine Hill : Novo Nordisk Clinical Trial Call Center Updated

A Long-term, Randomised, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

Mine Hill :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

New Brunswick :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Newark :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Sea Girt : Investigational Site Number 840203

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Sicklerville : Investigational Site Number 840295

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

South Plainfield :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Toms River : Novo Nordisk Clinical Trial Call Center Updated

A 26-week Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart BID and Insulin Degludec OD Plus Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin in Need of Treatment Intensification With Mealtime Insulin

Toms River : Novo Nordisk Clinical Trial Call Center Updated

A Long-term, Randomised, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

Toms River :

A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin Alone

Toms River : Investigational Site Number 840040

Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients

Toms River : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Study of How Dulaglutide Compares to Placebo in Participants With Type 2 Diabetes Who Are Also on Sulfonylurea Therapy (AWARD-8)

Toms River : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin Therapy

Toms Rivers :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Trenton : Site 26

A Study to Evaluate Safety and Efficacy of TTP054 for 12 Weeks in Subjects With Type 2 Diabetes

Trenton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Study of How Dulaglutide Compares to Placebo in Participants With Type 2 Diabetes Who Are Also on Sulfonylurea Therapy (AWARD-8)

Union : 1276.1.10015 Boehringer Ingelheim Investigational Site

Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes

Wall : Call for Information (Investigational Site 0127)

A Study of the Efficacy and Safety of MK-0431D (a Fixed-dose Combination of Sitagliptin and Simvastatin) for the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-266 AM1)

Albuquerque : Albuquerque Clinical Trials, Inc.

A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone

Albuquerque :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Albuquerque : Investigational Site Number 840269

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Albuquerque : Albuquerque Clinical Trials

Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus

Albuquerque : University of New Mexico Clinical and Translational Science Center

Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus

Albuquerque : Albuquerque Clinical Trials

Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus

Bronx : Einstein-Montefiore Institute for Clinical & Translational Research

Central Mechanisms that Regulate Glucose Metabolism in Humans

Bronx : Einstein-Montefiore Institute for Clinical & Translational Research

Closed Loop System in Type 1 Diabetes Management Comparison with Pramlintide vs Exenatide

Bronx : Einstein-Montefiore Institute for Clinical & Translational Research

Sitagliptin Dose Determination Study in Type 1 Diabetes

Bronx : Biomedical Research Alliance of New York

Type 2 Diabetes and Overt Nephropathy

Bronx : Biomedical Research Alliance of New York

Type 2 Diabetes Mellitus and Cardiovascular Outcomes - Adults

Lake Success : Biomedical Research Alliance of New York

Clinical trial to test how different doses of a study drug can help people with Type 2 Diabetes

Mineola : Winthrop University Hospital Clinical Trials Center

Diabetes - Type 2 Diabetes Mellitus

Mineola : Winthrop University Hospital Clinical Trials Center

Type 2 Diabetes

Mineola : Winthrop University Hospital Clinical Trials Center

Type 2 Diabetes - patients after an Acute Coronary Syndrome

Mineola : Winthrop University Hospital Clinical Trials Center

Type 2 Diabetes and Cardiovascular Disease

Albany : Novo Nordisk Clinical Trial Call Center Updated

A Long-term, Randomised, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

Albany : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)

Albany : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Binghamton : 1245.25.10131 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Bronx : Pfizer Investigational Site

A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy

Bronx :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Bronx : Albert Einstein College of Medicinie

Effect of GLP-1 on Insulin Biosynthesis and Turnover Rates

Bronx : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Bronx : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Study of How Dulaglutide Compares to Placebo in Participants With Type 2 Diabetes Who Are Also on Sulfonylurea Therapy (AWARD-8)

Brooklyn : 1276.10.11011 Boehringer Ingelheim Investigational Site

A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy

Brooklyn : Call for Information (Investigational Site 0021) Updated

A Study to Assess Cardiovascular Outcomes Following Treatment With MK-3102 in Participants With Type 2 Diabetes Mellitus (MK-3102-018 AM5)

Brooklyn : 1276.1.10029 Boehringer Ingelheim Investigational Site

Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes

Buffalo :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Buffalo : Women And Children'S Hopsital Of Buffalo

Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes

Endwell : GSK Investigational Site

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Engerix™-B in Adults With or Without Type 2 Diabetes Mellitus

Freash Meadows : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

Huntington :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Kingston :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Manlius : Central New York Clinical Research

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Mineola : Research Site

AMG 151 Amgen Protocol Number 20100761

Mineola : Novo Nordisk Clinical Trial Call Center

Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes

Mineola : Research Site

Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes

Mineola : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin Therapy

New Hyde Park : Investigational Site Number 840310

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

New Hyde Park : North Shore Diabetes and Endocrine Associates

Evaluate Safety of Technosphere® Insulin Inhalation Powder (TI Inhalation Powder) on Diabetic Subjects With Mild Obstructive Pulmonary Disease

New Hyde Park : N. Shore Diabetes & Endoc Assoc

Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes

New York : Medex Healthcare Research, Inc.

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

New York : Medex Healthcare Research, Inc.

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

New York :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

New York :

Colesevelam Pediatric Type 2 Diabetes Mellitus Study

New York : Novo Nordisk Clinical Trial Call Center

Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes

New York : MedHex Health

Evaluate Safety of Technosphere® Insulin Inhalation Powder (TI Inhalation Powder) on Diabetic Subjects With Mild Obstructive Pulmonary Disease

New York : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

New York : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

New York : Weill Cornell Medical College

Roux-en-Y-Gastric Bypass vs. Lifestyle Modification and Medical Therapy in the Treatment of Type 2 Diabetes

New York : Novartis Investigative Site

Safety & Effectiveness on Vascular Structure and Function of ACZ885 in Atherosclerosis and Either T2DM or IGT Patients

New York :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

North Massapequa : Digiovanna Institute For Medical Education & Research

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

North Massapequa : Digiovanna Institute For Medical Education & Research

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

North Massapequa : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin Therapy

Rochester : Novo Nordisk Clinical Trial Call Center Updated

A Long-term, Randomised, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

Rochester : Call for Information (Investigational Site 0014)

A Study of the Safety and Efficacy of MK-0431A in Pediatric Participants With Type 2 Diabetes Mellitus (MK-0431A-170 AM1)

Rochester : Site 12

A Study to Evaluate Safety and Efficacy of TTP054 for 12 Weeks in Subjects With Type 2 Diabetes

Rochester : 1245.25.10029 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Rochester :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Rochester : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

Rochester : Call for Information (Investigational Site 0011)

Study to Assess Safety & Efficacy of Sitagliptin as Initial Monotherapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants (MK-0431-083 AM1)

Rosedale :

Comparison of TAK-875 to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes

Saratoga Springs :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Sleepy Hollow : Novo Nordisk Clinical Trial Call Center

Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes

Smithtown : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)

Smithtown : Updated

A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities

Smithtown : 1245.25.10142 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Smithtown : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Springfield Gardens :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Staten Island : Novo Nordisk Clinical Trial Call Center Updated

A Long-term, Randomised, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

Staten Island : Call for Information (Investigational Site 0035) Updated

A Study to Assess Cardiovascular Outcomes Following Treatment With MK-3102 in Participants With Type 2 Diabetes Mellitus (MK-3102-018 AM5)

Staten Island : 1245.25.10096 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Staten Island : Investigational Site Number 840030

Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients

Valhalla :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

West Seneca : Novo Nordisk Clinical Trial Call Center Updated

A Long-term, Randomised, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

West Seneca : Southgate Medical Group

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

West Seneca : Southgate Medical Group

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

West Seneca : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy

West Seneca : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin Therapy

Westfield : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

Williamsville :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Charlotte : PMG Research of Charlotte

Type 2 Diabetes Study for Patients Not Currently Taking Diabetes Medications

Charlotte : American Health Research

Type 2 Diabetes Trial for patients taking more than 1500 mg of Metformin daily

Hickory : PMG Research of Hickory Updated

Do you have heart disease and Type 2 Diabetes or other risk factors for heart disease?

Hickory : PMG Research of Hickory Updated

Volunteers Needed For Type 2 Diabetes With A History Of Cardiovascular Disease

High Point : High Point Clinical Trials Center

Type 2 Diabetic Research Study

Raleigh : Multi-Specialty Research Associates of NC

Are you a diabetic patient taking medicine to treat your high cholesterol?

Raleigh : Multi-Specialty Research Associates of NC

Are you on insulin and suffer from Type 2 diabetes?

Raleigh : PMG Research of Raleigh

Concerned about Heart Disease? Do you also have Diabetes or Borderline Diabetes?

Raleigh : Multi-Specialty Research Associates of NC

Do you suffer from Type 2 diabetes?

Raleigh : PMG Research of Raleigh

Type 2 Diabetes Research Study for people who have had a recent ACS (Acute Coronary Syndrome) event such as heart attack or unstable angina

Salisbury : PMG Research of Salisbury

Cardiovascular Outcomes Study For Patients With Type 2 Diabetes

Salisbury : PMG Research of Salisbury

Do you have Type 2 diabetes?

Wilmington : PMG Research of Wilmington

Are your blood sugars not where they should be?

Wilmington : PMG Research of Wilmington

Cardiovascular Outcomes Study For Patients With Type 2 Diabetes

Wilmington : PMG Research of Wilmington

Type 2 Diabetes Research Study for people who have had a recent ACS (Acute Coronary Syndrome) event such as heart attack or unstable angina

Winston-Salem : PMG Research of Winston-Salem Updated

Cardiovascular Outcomes Study for Patients With Type 2 Diabetes

Winston-Salem : PMG Research of Winston-Salem

Getting Your Diabetes Under Control is job Number One!

Asheboro : Call for Information (Investigational Site 0010) Updated

Addition of MK-3102 to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin (MK-3102-022 AM3)

Asheville :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Asheville : Investigational Site Number 840247

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Ashville : Pfizer Investigational Site

A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy

Burlington : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Observational Study to Understand Challenges Associated With Progression of Insulin Therapy in Type 2 Diabetes

Burlington : 1245.25.10196 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Burlington : Investigational Site Number 840205

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Burlington : 1276.1.10022 Boehringer Ingelheim Investigational Site

Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes

Calabash : Call for Information (Investigational Site 0011) Updated

Addition of MK-3102 to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin (MK-3102-022 AM3)

Calabash : 1245.25.10207 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Calabash :

Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes

Calabash :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Charlotte : Pmg Research Of Charlotte

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Charlotte : Barat Research Group, Inc.

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Charlotte :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Charlotte :

Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes

Charlotte : PMG Research of Charlotte

Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus

Charlotte : PMG Research of Charlotte

Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus

Charlotte : Metrolina Internal Medicine

Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes

Charlotte : Barat Research Group, Inc.

Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes

Charlotte :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Durham : Novo Nordisk Clinical Trial Call Center Updated

A Long-term, Randomised, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

Durham :

A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Sulfonylurea Alone or Sulfonylurea Plus Metformin Therapy

Durham : 1245.25.10053 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Durham : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Durham : Diabetes Care Center

FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)

Durham :

Pharmacokinetics, Pharmacodynamics and Safety of Alogliptin in Children, Adolescents and Adults With Type 2 Diabetes Mellitus

Forsyth :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Greensboro : Call for Information (Investigational Site 0021)

A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM1)

Greensboro : Call for Information (Investigational Site 0011) Updated

A Study to Assess Cardiovascular Outcomes Following Treatment With MK-3102 in Participants With Type 2 Diabetes Mellitus (MK-3102-018 AM5)

Greensboro : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Observational Study to Understand Challenges Associated With Progression of Insulin Therapy in Type 2 Diabetes

Greensboro :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Greensboro : Investigational Site Number 840215

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Greensboro : Investigational Site Number 840296

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Greensboro :

Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes

Greensboro : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Greensboro : PharmQuest

Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus

Greensboro : PharmQuest

Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus

Greensboro : Novo Nordisk Clinical Trial Call Center

The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes

Greenville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)

Greenville : 1245.25.10010 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Greenville : East Carolina University

Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes

Hickory : Clinical Trials of America Inc

A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone

Hickory : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

High Point : Pfizer Investigational Site

Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus

Jacksonville : Call for Information (Investigational Site 0070) Updated

A Study to Assess Cardiovascular Outcomes Following Treatment With MK-3102 in Participants With Type 2 Diabetes Mellitus (MK-3102-018 AM5)

Jacksonville : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Lenoir : Call for Information (Investigational Site 0016)

A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM1)

Lenoir : Call for Information (Investigational Site 0038) Updated

A Study to Assess Cardiovascular Outcomes Following Treatment With MK-3102 in Participants With Type 2 Diabetes Mellitus (MK-3102-018 AM5)

Lenoir :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Lenoir : 1276.1.10002 Boehringer Ingelheim Investigational Site

Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes

Mooresville : Investigational Site Number 840271

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Mooresville :

Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes

Mooresville :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Morehead : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Morehead City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)

Morehead City : Diabetes & Endocrinology Consultants

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Morehead City :

Comparison of TAK-875 to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes

Morehead City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

Morehead City : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin Therapy

Morganton : Burke Primary Care

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Morganton : Burke Primary Care

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Morganton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Observational Study to Understand Challenges Associated With Progression of Insulin Therapy in Type 2 Diabetes

Morganton : Investigational Site Number 840275

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Morganton :

Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes

Morganton :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

North Myrtle Beach : 1276.10.11035 Boehringer Ingelheim Investigational Site

A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy

Raleigh : Novo Nordisk Clinical Trial Call Center Updated

A Long-term, Randomised, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

Raleigh : Research Site

AMG 151 Amgen Protocol Number 20100761

Raleigh :

Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes

Raleigh : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Raleigh : Pfizer Investigational Site

Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus

Rocky Mount : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)

Salisbury : Crescent Medical Research

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Salisbury : Pmg Research Of Salisbury

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Salisbury : Investigational Site Number 840011

Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients

Salisbury : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Salisbury : PMG Research of Salisbury

Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus

Shelby : Carolina Research Center

A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone

Smithfield :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Statesville : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Tabor City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Observational Study to Understand Challenges Associated With Progression of Insulin Therapy in Type 2 Diabetes

Tabor City : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy

Whiteville : Novo Nordisk Clinical Trial Call Center Updated

A 26-week Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart BID and Insulin Degludec OD Plus Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin in Need of Treatment Intensification With Mealtime Insulin

Whiteville : Novo Nordisk Clinical Trial Call Center Updated

A Long-term, Randomised, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

Wilmington : Pmg Research Of Wilmington Llc

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Wilmington : Call for Information (Investigational Site 0030)

A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM1)

Wilmington : INC Research Updated

Exenatide Pregnancy Registry - Type 2 Diabetes in Pregnancy

Wilmington : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Wilmington : New Hanover Medical Research

Safety and Efficacy of BGP-15 in Patients With Type 2 Diabetes Mellitus

Winston-salem : Updated

A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities

Winston-Salem : 1245.25.10188 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Winston-Salem :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Winston-Salem :

Comparison of TAK-875 to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes

Winston-Salem : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Winston-Salem : Piedmont Medical Research, LLC.

Safety and Efficacy of BGP-15 in Patients With Type 2 Diabetes Mellitus

Bismarck : Legacy Pharma Research

Type 2 Diabetes and Acute Coronary Syndrome

Bismarck : Research Site

AMG 151 Amgen Protocol Number 20100761

Bismarck :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Fargo : Lillestol Research

A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone

Fargo : Lillestol Research

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Fargo : Lillestol Research

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Fargo : Research Site

AMG 151 Amgen Protocol Number 20100761

Minot :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Cincinnati : Community Research

Taking Insulin for your Type-II Diabetes

Cincinnati : Community Research

Taking Metformin alone or in combination for your Type-II Diabetes?

Cincinnati : Community Research

Type 2 Diabetes

Cincinnati : Community Research

Type-II Diabetes

Cincinnati : Community Research

Type-II Diabetes & High Blood Pressure

Cincinnati : Community Research

Type-II Diabetes & High Blood Pressure

Cleveland : Rapid Medical Research, Inc. (RMR)

Are you a Type 2 Diabetic taking metformin but still struggle to achieve adequate blood sugar levels?

Cleveland : Rapid Medical Research, Inc. (RMR)

Are you living with uncontrolled Type 2 Diabetes?

Cleveland : Rapid Medical Research, Inc. (RMR)

Hepatitis B Vaccine Clinical Research Study

Cleveland : Rapid Medical Research, Inc. (RMR)

Type II Diabetes & Cardiovascular Disease

Columbus : Columbus Clinical Research

Diabetes

Dayton : Providence Health Partners - Center for Clinical Research

Type II Diabetes - Diet Controlled

Dayton : Providence Health Partners - Center for Clinical Research

Type II Diabetes on Single or Multiple Medications

Akron :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Akron : Investigational Site Number 840241

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Akron : 1218.56.01005 Boehringer Ingelheim Investigational Site

Finding a Safe and Effective Dose of Linagliptin in Pediatric Patients With Type 2 Diabetes

Akron : Call for Information (Investigational Site 0014)

Study to Assess Safety & Efficacy of Sitagliptin as Initial Monotherapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants (MK-0431-083 AM1)

Akron : Akron Children'S Hospital

Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes

Athens :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Athens : Ohio University College Of Osteopathic Medicine

Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes

Beachwood : Call for Information (Investigational Site 0039)

A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM1)

Beachwood : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Study of How Dulaglutide Compares to Placebo in Participants With Type 2 Diabetes Who Are Also on Sulfonylurea Therapy (AWARD-8)

Beavercreek : Clinical Inquest Center, Ltd.

A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone

Beavercreek : Clinical Inquest Center, Ltd.

Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus

Beavercreek : Clinical Inquest Center, Ltd.

Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus

Canal Fulton : Call for Information (Investigational Site 0073) Updated

A Study to Assess Cardiovascular Outcomes Following Treatment With MK-3102 in Participants With Type 2 Diabetes Mellitus (MK-3102-018 AM5)

Canal Fulton : Call for Information (Investigational Site 0090)

Study to Assess Safety & Efficacy of Sitagliptin as Initial Monotherapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants (MK-0431-083 AM1)

Canton : Clinical Research Limited

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Carlisle :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Cincinnati : Novo Nordisk Clinical Trial Call Center Updated

A Long-term, Randomised, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

Cincinnati : Community Research

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Cincinnati : Community Research

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Cincinnati : Site 14

A Study to Evaluate Safety and Efficacy of TTP054 for 12 Weeks in Subjects With Type 2 Diabetes

Cincinnati : Research Site

AMG 151 Amgen Protocol Number 20100761

Cincinnati : 1245.25.10086 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Cincinnati : 1245.25.10060 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Cincinnati :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Cincinnati :

Comparison of TAK-875 to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes

Cincinnati : Pfizer Investigational Site

Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus

Cincinnati : Novartis Investigative Site

Safety & Effectiveness on Vascular Structure and Function of ACZ885 in Atherosclerosis and Either T2DM or IGT Patients

Cincinnati : Sterling Research Grp, Ltd.

Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes

Cincinnati : 1276.1.10005 Boehringer Ingelheim Investigational Site

Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes

Cincinnati : The Carl and Edyth Lindner Center for Research and Education at The Christ Hospital

Safety Study of Mesenchymal Precursor Cells in Type 2 Diabetes

Cincinnati : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy

Cincinnatti : Gottschlich, Gregory

Safety, Tolerability, Pharmacokinetics,Pharmacodynamics Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus

Cleveland : Novo Nordisk Clinical Trial Call Center Updated

A Long-term, Randomised, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

Cleveland : Research Site

AMG 151 Amgen Protocol Number 20100761

Cleveland : Investigational Site Number 840330

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Cleveland :

Comparison of TAK-875 to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes

Cleveland : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Cleveland : GSK Investigational Site

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Engerix™-B in Adults With or Without Type 2 Diabetes Mellitus

Cleveland :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Columbus : Investigational Site Number 840307

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Columbus : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

Dayton : Research Site

AMG 151 Amgen Protocol Number 20100761

Dayton : 1245.25.10137 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Dayton :

Comparison of TAK-875 to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes

Dayton : Providence Health Partners - Center for Clinical Reseach

Safety Study of Mesenchymal Precursor Cells in Type 2 Diabetes

Dayton : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin Therapy

Delaware : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Observational Study to Understand Challenges Associated With Progression of Insulin Therapy in Type 2 Diabetes

Delaware : 1245.25.10138 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Franklin : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy

Gallipolis : Call for Information (Investigational Site 0002)

A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM1)

Gallipolis : Updated

A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities

Gallipolis : Call for Information (Investigational Site 0007) Updated

A Study to Assess Cardiovascular Outcomes Following Treatment With MK-3102 in Participants With Type 2 Diabetes Mellitus (MK-3102-018 AM5)

Gallipolis : 1276.1.10011 Boehringer Ingelheim Investigational Site

Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes

Gallipolis :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Kettering : Wells Institute For Health Awareness

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Kettering : Wells Institute For Health Awareness

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Kettering : Call for Information (Investigational Site 0014)

A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM1)

Kettering : Research Site

AMG 151 Amgen Protocol Number 20100761

Kettering : 1245.25.10156 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Kettering : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Lorain :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Marion :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Marion :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Mason : Novo Nordisk Clinical Trial Call Center Updated

A Long-term, Randomised, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

Mason : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy

Maumee : Novo Nordisk Clinical Trial Call Center Updated

A Long-term, Randomised, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

Maumee :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Maumee :

Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes

Mentor : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Middleburg Heights : Cleveland Sleep Research Center

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Middleburg Heights : Cleveland Sleep Research Center

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Middleburg Heights :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Perrysburg : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study Comparing the Effect of Dulaglutide With Liraglutide in Type 2 Diabetes

Perrysburg : Clinical Research Source, Inc

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Perrysburg : Call for Information (Investigational Site 0013)

A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM1)

Springfield :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Toledo : Call for Information (Investigational Site 0089) Updated

A Study to Assess Cardiovascular Outcomes Following Treatment With MK-3102 in Participants With Type 2 Diabetes Mellitus (MK-3102-018 AM5)

Toledo :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Toledo : Novo Nordisk Clinical Trial Call Center

Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes

Toledo : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Toledo : University of Toledo/Promedica

PK Study of Dapagliflozin in Pediatric Subjects With T2DM

Toledo : Call for Information (Investigational Site 0096)

Study to Assess Safety & Efficacy of Sitagliptin as Initial Monotherapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants (MK-0431-083 AM1)

Wadsworth : Family Practice Center Of Wadsworth, Inc.

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Willoughby Hills : Pfizer Investigational Site

A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy

Zanesville : 1245.25.10192 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Zanesville :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Zanesville : Physicians Research, Inc.

Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes

Oklahoma City : Harold Hamm Diabetes Center at the University of Oklahoma - Clinical Trials Unit

The Harold Hamm Diabetes Center in Oklahoma City, OK is looking for volunteers diagnosed with type 2 diabetes and inadequate blood sugar control, currently taking Metformin only, to participate in a research study evaluating the effectiveness and safety of an investigational combination of approved medications.

Oklahoma City : Harold Hamm Diabetes Center at the University of Oklahoma - Clinical Trials Unit

The Harold Hamm Diabetes Center in Oklahoma City, OK is looking for volunteers diagnosed with type 2 diabetes and moderate renal (kidney) impairment to participate in a research study evaluating the effectiveness and safety of an investigational combination formula.

Tulsa : Vital Prospects Clinical Research Institute, P.C.

Have HIGH BLOOD PRESSURE and DIABETES TYPE II? We need your help in a study to evaluate the efficacy and safety of Aliskiren administered in combination with Valsartan versus Valsartan alone.

Bartlesville :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Norman : Research Site

AMG 151 Amgen Protocol Number 20100761

Norman : 1245.25.10114 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Norman : Investigational Site Number 840229

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Norman :

Comparison of TAK-875 to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes

Norman :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Oklahoma City : Novo Nordisk Clinical Trial Call Center Updated

A Long-term, Randomised, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

Oklahoma City : Integris Family Care Central

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Oklahoma City : Sooner Clinical Research

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Oklahoma City : Paradigm Research Professionals, Llc

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Oklahoma City : Call for Information (Investigational Site 0005) Updated

Addition of MK-3102 to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin (MK-3102-022 AM3)

Oklahoma City : Research Site

AMG 151 Amgen Protocol Number 20100761

Oklahoma City :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Oklahoma City :

Colesevelam Pediatric Type 2 Diabetes Mellitus Study

Oklahoma City :

Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes

Oklahoma City : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Oklahoma City : Infinity Research Group, LLC

Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus

Oklahoma City : Infinity Research Group, LLC

Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus

Oklahoma City :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Oklahoma City : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy

Yukon : Integris Family Care Yukon

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Yukon : Integris Family Care Yukon

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Yukon :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Eugene : Clinical Trials of America, Inc

Millions of people struggle to manage their Type 2 Diabetes Are you one of them ?

Ashland : Call for Information (Investigational Site 0004) Updated

Addition of MK-3102 to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin (MK-3102-022 AM3)

Bend :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Bend : Investigational Site Number 840219

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Corvallis :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Eugene : Willamette Valley Clinical Studies

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Eugene : Willamette Valley Clinical Studies

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Eugene : 1245.25.10082 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Gresham : Cyn3rgy Research

Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes

Portland :

A Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus Who Have Not Previously Received Anti-Hyperglycemic Therapy

Portland :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Portland : Oregon Health & Science University

Effects of DPP-4 Inhibition on Triglycerides

Portland : Oregon Health and Science University

FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)

Portland : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

Altoona : Blair Medical Associates, Inc. Clinical Trials Dept.

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Cardiovascular Outcomes Following Treatment With Alogliptin in Addition to Standard of Care in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Altoona : Blair Medical Associates, Inc. Clinical Trials Dept.

Canakinumab

Altoona : Blair Medical Associates, Inc. Clinical Trials Dept.

Exenatide

Altoona :

A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin Alone

Altoona :

A Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus Who Have Not Previously Received Anti-Hyperglycemic Therapy

Altoona : Call for Information (Investigational Site 0128)

A Study of the Efficacy and Safety of MK-0431D (a Fixed-dose Combination of Sitagliptin and Simvastatin) for the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-266 AM1)

Altoona :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Altoona : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Altoona : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin Therapy

Beaver : Novo Nordisk Clinical Trial Call Center Updated

A Long-term, Randomised, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

Beaver :

A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin Alone

Beaver : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy

Bethlehem : Pfizer Investigational Site

A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy

Broomall : Southeastern Pa Medical Institute

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Broomall : Southeastern Pa Medical Institute

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Camp Hill : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Clairton : 1245.25.10154 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Downingtown : Call for Information (Investigational Site 0051) Updated

A Study to Assess Cardiovascular Outcomes Following Treatment With MK-3102 in Participants With Type 2 Diabetes Mellitus (MK-3102-018 AM5)

Erie : Westminster Family Medicine

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Feasterville : Abington Memorial Hos/Feasterville Family Health Care Center

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Feasterville : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Feasterville Trevose : Abington Memorial Hos/Feasterville Family Health Care Center

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Feasterville Trevose : 1245.25.10052 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Fleetwood : Integrated Medical Group Pc / Fleetwood Medical Assoc.

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Fleetwood : 1245.25.10069 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Fleetwood :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Harleysville :

Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes

Harleysville :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Hershey : Novo Nordisk Clinical Trial Call Center

Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes

Indiana : 1245.25.10050 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Jenkintown : The Clinical Trial Center, Llc

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Jenkintown : The Clinical Trial Center, Llc

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Johnstown : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Observational Study to Understand Challenges Associated With Progression of Insulin Therapy in Type 2 Diabetes

Lancaster :

Comparison of TAK-875 to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes

Landsdale : Detweiler Family Practice

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Landsdale : Detweiler Family Practice

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Langhorne :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Lansdale : Updated

A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities

Lansdale : 1245.25.10009 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Lansdale : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Levittown : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Observational Study to Understand Challenges Associated With Progression of Insulin Therapy in Type 2 Diabetes

Levittown :

Comparison of TAK-875 to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes

Levittown :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Newport : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Norristown :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Philadelphia : Novo Nordisk Clinical Trial Call Center Updated

A Long-term, Randomised, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

Philadelphia : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)

Philadelphia : Arcuri Clinical Research Llc

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Philadelphia : Philadelphia Health Associates - Adult Medicine

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Philadelphia : Arcuri Clinical Research Llc

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Philadelphia : Philadelphia Health Associates - Adult Medicine

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Philadelphia : 1245.25.10214 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Philadelphia : University of Pennsylvania Center for Weight and Eating Disorders

Blood Glucose Stability and Variability on Two Diets

Philadelphia :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Philadelphia :

Colesevelam Pediatric Type 2 Diabetes Mellitus Study

Philadelphia : Investigational Site Number 840240

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Philadelphia : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Philadelphia :

Pharmacokinetics, Pharmacodynamics and Safety of Alogliptin in Children, Adolescents and Adults With Type 2 Diabetes Mellitus

Philadelphia : Children's Hospital of Philadelphia

PK Study of Dapagliflozin in Pediatric Subjects With T2DM

Philadelphia :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Philadelphia : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy

Pittsburg : 1245.25.10173 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Pittsburgh : Novo Nordisk Clinical Trial Call Center Updated

A 26-week Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart BID and Insulin Degludec OD Plus Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin in Need of Treatment Intensification With Mealtime Insulin

Pittsburgh : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)

Pittsburgh : 1245.25.10197 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Pittsburgh : 1245.25.10149 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Pittsburgh :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Pittsburgh : Novo Nordisk Clinical Trial Call Center

Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes

Pittsburgh : Novo Nordisk Clinical Trial Call Center

The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes

Pittsburgh : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin Therapy

Reading : Research Across America

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Reading : Research Across America

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Schwenksville :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Scotland :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Scottdale : 1245.25.10159 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Scranton :

A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin Alone

Sellersville :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Tipton :

A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin Alone

Tipton :

A Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus Who Have Not Previously Received Anti-Hyperglycemic Therapy

Tipton : 1245.25.10162 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Tipton : Investigational Site Number 840308

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Tipton : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Uniontown : Pfizer Investigational Site

A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy

Uniontown : Preferred Primary Care Physicians

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Uniontown : Pish Medical Associates

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Uniontown : Pish Medical Associates

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Uniontown : Preferred Primary Care Physicians

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Uniontown : 1245.25.10146 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Uniontown :

Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes

Uniontown :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Upper Darby : The Chandler & Thakur Medical Group

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Upper Darby : The Chandler & Thakur Medical Group

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Upper St Clair : Novo Nordisk Clinical Trial Call Center Updated

A Long-term, Randomised, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

Upper St Clair : Novo Nordisk Clinical Trial Call Center

The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes

Yardley :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

East Providence :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Pawtucket : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Providence : Pfizer Investigational Site

A Phase 2 Multi-Center Study To Evaluate The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist In Adults With Type 2 Diabetes And Overt Nephropathy

Warwick : Greater Providence Clinical Research, Llc

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Warwick : Greater Providence Clinical Research, Llc

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Anderson : Internal Medicine Associates of Anderson, P.A.

New Investigational Medication Study for Patients with Type 2 Diabetes and Increased Cardiovascular Risks

Clinton : Palmetto Clinical Trial Services, LLC

Diabetes and Cardiovascular Disease

Clinton : Palmetto Clinical Trial Services, LLC

Diabetes and Heart Disease

Clinton : Palmetto Clinical Trial Services, LLC

Do you have type 2 diabetes?

Mt Pleasant : PMG Research of Charleston

Cardiovascular Outcomes Study For Patients With Type 2 Diabetes

Anderson : Southeastern Research Associates, Inc.

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Anderson : 1245.25.10070 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Beaufort : Lowcountry Medical Group, Llc

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Beaufort : Lowcountry Medical Group, Llc

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Charleston : Medical Research South

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Charleston : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Observational Study to Understand Challenges Associated With Progression of Insulin Therapy in Type 2 Diabetes

Charleston : 1245.25.10044 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Charleston : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Clinton : Updated

A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities

Clinton : 1245.25.10129 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Columbia : Pfizer Investigational Site

A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy

Columbia : Call for Information (Investigational Site 0061) Updated

A Study to Assess Cardiovascular Outcomes Following Treatment With MK-3102 in Participants With Type 2 Diabetes Mellitus (MK-3102-018 AM5)

Columbia : Novo Nordisk Clinical Trial Call Center

Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes

Florence :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Greenville :

Colesevelam Pediatric Type 2 Diabetes Mellitus Study

Greenville : Upstate Pharmaceutical Research

Safety and Efficacy of BGP-15 in Patients With Type 2 Diabetes Mellitus

Greer : Novo Nordisk Clinical Trial Call Center Updated

A Long-term, Randomised, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

Greer :

A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Sulfonylurea Alone or Sulfonylurea Plus Metformin Therapy

Greer : 1245.25.10002 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Greer : Investigational Site Number 840252

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Greer :

Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes

Greer : Mountain View Clinical Research

Safety and Efficacy of BGP-15 in Patients With Type 2 Diabetes Mellitus

Greer : 1276.1.10008 Boehringer Ingelheim Investigational Site

Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes

Greer :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Greer : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy

Hodges : 1245.25.10132 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Mount Pleasant : Site 6

A Study to Evaluate Safety and Efficacy of TTP054 for 12 Weeks in Subjects With Type 2 Diabetes

Mount Pleasant : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Mt. Pleasant : 1245.25.10140 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Murrells Inlet : Updated

A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities

Murrells Inlet : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

Myrtle Beach : Novo Nordisk Clinical Trial Call Center Updated

A Long-term, Randomised, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

Myrtle Beach : 1245.25.10065 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Myrtle Beach : 1245.25.10127 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

North Myrtle Beach : North Myrtle Beach Family Practice

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

North Myrtle Beach : North Myrtle Beach Family Practice

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

North Myrtle Beach : 1245.25.10170 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Orangeburg : Pfizer Investigational Site

A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy

Pawleys Island : Pawleys Pediatrics And Adult Medicine

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Pelzer : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy

Simpsonville : Hillcrest Clinical Reseach, Llc

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Simpsonville : Hillcrest Clinical Reseach, Llc

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Simpsonville :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Simpsonville : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy

Spartanburg : Call for Information (Investigational Site 0042) Updated

A Study to Assess Cardiovascular Outcomes Following Treatment With MK-3102 in Participants With Type 2 Diabetes Mellitus (MK-3102-018 AM5)

Spartanburg :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Spartanburg : Investigational Site Number 840237

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Spartanburg :

Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes

Spartanburg : Novo Nordisk Clinical Trial Call Center

The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes

Spartanburg : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy

Summerville : Call for Information (Investigational Site 0044) Updated

A Study to Assess Cardiovascular Outcomes Following Treatment With MK-3102 in Participants With Type 2 Diabetes Mellitus (MK-3102-018 AM5)

Sumter : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)

Sumter : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin Therapy

Taylors : Southeastern Research Associates, Inc.

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Taylors : Southeastern Research Associates, Inc.

Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus

Taylors : Southeastern Research Associates, Inc.

Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus

Union : 1245.25.10171 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Varnville : Updated

A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities

Dakota Dunes : Updated

A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities

Dakota Dunes : Investigational Site Number 840294

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Sioux Falls :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Bristol : PMG Research of Bristol

Are you a Type 2 Diabetes Patient looking for a simple way to take your insulin?

Bristol : PMG Research of Bristol

Are your blood sugars not where they need to be?

Bristol : PMG Research of Bristol

Cardiovascular Outcomes Study For Patients With Type 2 Diabetes

Clarksville : Alpha Clinical Research, LLC

When your Type 2 Diabetes is out of control, finding harmony is essential.

Knoxville : PMG Research of Knoxville Updated

Getting Your Diabetes Under Control is job Number One!

Nashville : Dial Research Associates, Inc.

Clinical trial to evaluate an investigational type 2 oral diabetes medication compared to a marketed diabetes medication.

Athens : Athens Medical Group

Safety and Efficacy of BGP-15 in Patients With Type 2 Diabetes Mellitus

Bartlett :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Brentwood : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy

Bristol : Holston Medical Group

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Bristol : Holston Medical Group

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Bristol : 1245.25.10054 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Bristol : Investigational Site Number 840260

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Bristol : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Bristol : Holston Medical Group

Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes

Chattanooga : Novo Nordisk Clinical Trial Call Center Updated

A Long-term, Randomised, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

Chattanooga : Chattanooga Research & Medicine, Pllc

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Chattanooga : Call for Information (Investigational Site 0003)

A Study of MK-3102 in Participants With Type 2 Diabetes Mellitus With Chronic Kidney Disease or Kidney Failure on Dialysis (MK-3102-019 AM3)

Chattanooga : Updated

A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities

Chattanooga : 1245.25.10057 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Chattanooga : 1245.25.10036 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Chattanooga : Investigational Site Number 840262

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Chattanooga : Investigational Site Number 840032

Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients

Chattanooga : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy

Chattanooga : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin Therapy

Crossville :

Comparison of TAK-875 to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes

Fayetteville : Call for Information (Investigational Site 0033) Updated

A Study to Assess Cardiovascular Outcomes Following Treatment With MK-3102 in Participants With Type 2 Diabetes Mellitus (MK-3102-018 AM5)

Franklin :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Germantown :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Humboldt : 1276.1.10017 Boehringer Ingelheim Investigational Site

Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes

Jackson :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Jackson : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Jackson :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Johnson City : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Kingsport : Novo Nordisk Clinical Trial Call Center Updated

A 26-week Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart BID and Insulin Degludec OD Plus Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin in Need of Treatment Intensification With Mealtime Insulin

Kingsport : Novo Nordisk Clinical Trial Call Center Updated

A Long-term, Randomised, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

Kingsport : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study Comparing the Effect of Dulaglutide With Liraglutide in Type 2 Diabetes

Kingsport : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

An Observational Study to Understand Challenges Associated With Progression of Insulin Therapy in Type 2 Diabetes

Kingsport : 1245.25.10046 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Kingsport : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Kingsport : Holston Medical Group

Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus

Kingsport :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Kingsport : Holston Medical Group

Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes

Kingsport : Novo Nordisk Clinical Trial Call Center

The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes

Kingsport : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy

Kingsport : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin Therapy

Knoxville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)

Knoxville :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Knoxville : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Knoxville : New Phase Research & Development

Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus

Knoxville : New Phase Research & Development

Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus

McKenzie : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Memphis : Novo Nordisk Clinical Trial Call Center Updated

A Long-term, Randomised, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

Memphis : Southwind Medical Specialists

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Memphis : 1245.25.10143 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Memphis :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Memphis : Novo Nordisk Clinical Trial Call Center

Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes

Memphis :

Pharmacokinetics, Pharmacodynamics and Safety of Alogliptin in Children, Adolescents and Adults With Type 2 Diabetes Mellitus

Memphis : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

Memphis : Research Site

Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes

Memphis : Methodist Le Bonheur Hlthcare

Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes

Nashville : Novo Nordisk Clinical Trial Call Center Updated

A Long-term, Randomised, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

Nashville :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Nashville :

Colesevelam Pediatric Type 2 Diabetes Mellitus Study

Nashville : Research Site

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Nashville : GSK Investigational Site

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Engerix™-B in Adults With or Without Type 2 Diabetes Mellitus

Nashville : Vanderbilt Diabetes Center

Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes

Nashville :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Nashville : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin Therapy

Tullahoma, : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin Therapy

Dallas : Galenos Research

Diabetes can be unpredictable.

Dallas : North Texas and Endocrine Center

Type 2 Diabetes with Cardiovascular

Dallas : ACRC TRIALS

Type 2 Diabetes?

Houston : DM Clinical Research

Diabetes and Acute Coronary Syndrome - Houston,TX

Houston : DM Clinical Research

Type 2 Diabetes

Houston : DM Clinical Research

Type 2 Diabetes (ages 65+) - Houston, TX

Houston : DM Clinical Research

Type 2 Diabetes Mellitus

San Antonio : Sun Research Institute

Are you taking Lantus to treat your Type 2 Diabetes?

Arlington : Arlington Family Research Center, Inc.

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Arlington : Arlington Family Research Center, Inc.

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Arlington : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin Therapy

Austin : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)

Austin : Novo Nordisk Clinical Trial Call Center

The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin Therapy

Beaumont :

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Boerne : Call for Information (Investigational Site 0017)

A Study of the Safety and Efficacy of MK-0431A in Pediatric Participants With Type 2 Diabetes Mellitus (MK-0431A-170 AM1)

Boerne : Call for Information (Investigational Site 0015)

Study to Assess Safety & Efficacy of Sitagliptin as Initial Monotherapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants (MK-0431-083 AM1)

Carrollton :

Comparison of TAK-875 to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes

Carrollton :

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Corpus Christi : 3rd Coast Research Associates

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Corpus Christi : Call for Information (Investigational Site 0010)

A Study of MK-3102 in Participants With Type 2 Diabetes Mellitus With Chronic Kidney Disease or Kidney Failure on Dialysis (MK-3102-019 AM3)

Corpus Christi : Updated

A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities

Corpus Christi : Call for Information (Investigational Site 0084) Updated

A Study to Assess Cardiovascular Outcomes Following Treatment With MK-3102 in Participants With Type 2 Diabetes Mellitus (MK-3102-018 AM5)

Corpus Christi : 1245.25.10075 Boehringer Ingelheim Investigational Site

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.

Corpus Christi : Investigational Site Number 840342

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Corpus Christi : Investigational Site Number 840034

Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients

Corpus Christi : Padre Coast Clinical Research

Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes

Dallas : Novo Nordisk Clinical Trial Call Center Updated

A 26-week Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart BID and Insulin Degludec OD Plus Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin in Need of Treatment Intensification With Mealtime Insulin

Dallas : Novo Nordisk Clinical Trial Call Center Updated

A Long-term, Randomised, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

Dallas : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)

Dallas : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study Comparing the Effect of Dulaglutide With Liraglutide in Type 2 Diabetes

Dallas :

A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin Alone

Dallas :

A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Sulfonylurea Alone or Sulfonylurea Plus Metformin Therapy

Dallas : Internal Medicine Clinical Reaseach

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Dallas : Krk Medical Research

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Dallas : Renaissance Clinical Research And Hypertension Pllc

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Dallas : Research Institute Of Dallas

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Dallas : Krk Medical Research

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Dallas : Renaissance Clinical Research And Hypertension Pllc

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Dallas : Internal Medicine Clinical Research

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Diabetes Mellitus, Type 2 Clinical Trials

Alabama

Alaska

Arizona

Arkansas

California

Colorado

Connecticut

Delaware

District of Columbia

Florida

Georgia

Hawaii

Idaho

Illinois

Indiana

Iowa

Kansas

Kentucky

Louisiana

Maine

Maryland

Massachusetts

Michigan

Minnesota

Mississippi

Missouri

Montana

Nebraska

Nevada

New Hampshire

New Jersey

New Mexico

New York

North Carolina

North Dakota

Ohio

Oklahoma

Oregon

Pennsylvania

Rhode Island

South Carolina

South Dakota

Tennessee

Texas